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2. Abbreviations and definitions 
AA   Arachidonic acid  
AC   Ampullary cancer  
AJCC  American Joint Committee of Cancer Staging 
αSMA   α- smooth muscle actin 
EGF  Epidermal growth factor 
cAMP  Cyclic adenosine monophosphate  
COX-2   Cyclooxygenase type 2 
DBC  Distal bile duct cancer 
DC  Duodenal cancer 
ECM   Extracellular matrix 
IHC  Immunohistochemistry 
IL   Interleukin 
LNR  Lymph node ratio 
PC   Pancreatic cancer 
PDGF  Platelet-derived growth factor 
PGE2   Prostaglandin E2   
PSC   Pancreatic stellate cells 
TGFβ   Transforming growth factor beta  
UICC   Union for International Cancer Control 
WHO  World Health Organisation 
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4. Summary 
 
Primary adenocarcinomas located in the pancreatic head may arise from the distal bile duct, the 
ampulla, the periampullary duodenum, and the pancreatic tissue itself. These tumours are distinct 
cancer entities whose pathobiology, staging, and clinical course have unique features.  
 
The aims of the present study were to investigate how the standardized histopathological examination 
protocol ensures correct classification of tumour origin of pancreatic head adenocarcinomas. 
Furthermore, we examined how different approaches to assessment of lymph node metastases and 
expression of cyclooxygenase-2 (COX-2) in the tumours can predict long-term outcome. Finally, we 
assessed COX-2 expression and effects of PGE2 on cells proliferation and collagen synthesis in 
pancreatic stellate cells in vitro. 
 
The precise anatomical site of origin is often difficult to establish during preoperative investigations 
or during surgery and therefore the final diagnosis is always the result of the histopathological 
examination. The predetermined diagnostic criteria, with special focus on the anatomical site of 
origin, are essential to improve the accuracy of diagnosis. Furthermore, high workload per 
pathologist increases the precision of the histopathologic diagnosis.  
 
The presence of lymph node metastasis is a major determinant of long-term survival in pancreatic 
head cancers. In patients operated with pancreatoduodenectomy, N status and LNR are superior to the 
number of metastatic node as prognostics indicators. The predictive value of these variables depends 
on the cancer origin. In ampullary and distal bile duct cancer, N status discriminates between 
subgroups of patients with different long-term survival whereas in pancreatic cancer, LNR is clearly 
more powerful in prognostic subclassification.  In patients with pancreatic cancer, multivariate 
analysis identified LNR > 0.2 as an independent predictor of poor long-term survival. LNR could 
therefore be proposed as a standard, alternative measure of nodal involvement in the pancreatic 
cancer.  
 
Overexpression of COX-2 has been described in several tumours, however the data on the prognostic 
importance of COX-2 in pancreatic head adenocarcinomas are inconsistent. In our study COX-2 is 
overexpressed in >70% of pancreatic, ampullary and distal bile duct cancers and is associated with 
the histopathological type of differentiation, with the degree of differentiation, and with a favourable 
prognosis. In pancreatic cancer, in a multivariate model, COX-2 negative tumours and LNR > 0.2, 
independently predicted poor prognosis.  
 
When assessed by immunohistochemistry, COX-2 is mainly expressed in pancreatic carcinoma cells, 
and these cells are regarded as the main source of PGE2 in pancreatic cancer tumour tissue. COX-2 
was not detected in the stroma, however COX-2 was detected in the cultured pancreatic stellate cells 
(PSC), and could be further induced by interleukin-1β (IL-1β), epidermal growth factor (EGF), 
thrombin, and PGE2, but not by transforming growth factor-β1 (TGFβ). Treatment of PSC with PGE2 
suppressed both TGFβ-stimulated collagen synthesis and PDGF-stimulated DNA synthesis, 
suggesting that inhibition of COX-2 may inadvertently accelerate fibrosis progression in pancreatic 
cancer. 
 
This thesis confirms that standardised histopathological evaluation after pancreatoduodenectomy 
with special focus on the tumour origin, lymph node assessment, degree and type of differentiation is 
necessary to obtain accurate and reliable survival estimates. Furthermore, our findings of the COX-2 
expression in the tumours, and the PGE2 effects on pancreatic stellate cells, revealed new aspects of 
biological mechanisms involved in progression of pancreatic cancer. 
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5. Introduction  
 
5.1 The pancreatic gland  
The pancreas is a glandular organ, oval-shaped, located retroperitoneally on the posterior upper part 
of the abdomen, behind the stomach, across the lumbar (L1-2) spine (Fig.1). The pancreatic head 
constitutes about two- thirds of the pancreatic volume and the body (corpus) and tail (cauda) make up 
the remaining of the pancreatic parenchymal mass (Fig.2). The head of the pancreas lays in the 
duodenal loop in front of the inferior vena cava (IVC) and the left renal vein. The uncinate process is 
an extension of the inferior half of the head toward the left; it is of varying size and is wedged 
between the superior mesenteric vessels (vein and artery) in front and the aorta behind it. The body 
and tail of the pancreas run obliquely upward to the left in front of the aorta and left kidney. The 
narrow tip of the tail of the pancreas reaches the splenic hilum in the splenorenal (lienorenal) 
ligament. The pancreatic neck is the arbitrary junction between the head and body of the pancreas, 
with the portal vein immediately adjacent behind.  
 
 
Figure 1 
The duodenum and pancreas. Henry Gray. Anatomy of the Human Body, 1918 (copyright expired) 
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Figure 2 
The pancreatic gland. Henry Gray. Anatomy of the Human Body, 1918 (copyright expired) 
 
The pancreas is classified as a heterocrine gland because it contains both endocrine and exocrine 
glandular tissue.  Most of the pancreatic tissue mass (80-90%) is composed of exocrine tissue. The 
endocrine portion of the pancreas is composed of small clusters of cells called islets of Langerhans, 
which are scattered throughout the exocrine tissue. There are two main types of endocrine cells that 
make up the islets: alpha cells and beta cells. Both types are involved in glucose homeostasis - alpha 
cells produce glucagon and beta cells produce insulin. The exocrine tissue is arranged into many 
small masses known as acini. Acini are small grapes -like clusters of exocrine cells that surround tiny 
ducts. The exocrine cells in the acini produce digestive enzymes in response to stimuli from the 
stomach and the duodenum1. After the enzymes are secreted from the cells, they enter the ducts, 
where ductal cells add mucous and bicarbonate to the enzyme mixture. The ducts of many acini 
connect to form larger ducts culminating in the major pancreatic duct of Wirsung, which empty into 
the duodenum at the papilla of Vater (Fig.2). In some anatomical variants the main and accessory 
pancreatic ducts failure to fuse and form pancreas divisum where the accessory pancreatic duct (of 
Santorini) drains the body and tail of pancreas via the additional minor papilla into the duodenum. 
The common distal bile duct enters the pancreatic gland from behind and joins the main pancreatic 
duct, forming the ampulla of Vater. There are a number of variations in the anatomy of the pancreatic 
ductal system and their relationship to the common biliary duct2. Usually, there is a short common 
channel –which forms ampulla of Vater. However, in some cases, the major pancreatic duct and the 
common bile duct do not fuse and enter the duodenum thorugh two separate openings. In those cases, 
the ampulla of Vater, as a separate anatomical site, does not exist.   
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5.2 Pancreatic head adenocarcinomas     
Primary adenocarcinomas located in the pancreatic head may arise from the pancreatic tissue itself, 
the ampulla of Vater, the distal bile duct and the periampullary duodenum. These adenocarcinomas 
have different biological and pathological features, as well as clinical course and overall prognosis3. 
These adenocarcinomas have often been collectively named periampullary carcinomas. Although the 
term periampullary carcinoma might be a good term to define this heterogeneous group of neoplasms, 
there is substantial inconsistency in the published literature regarding its definition4. Most often, in 
the surgical literature, this term is referred to carcinomas which can be removed by 
pancreatoduodenectomy, irrespectively of the tumour origin (duodenal, ampullary, distal bile duct or 
pancreatic)5;6. However, in other publications, this term might be restricted only to tumours arising 
from the ampulla of Vater or/and duodenum7. Others defined it as tumours arise near (e.g. < 2 cm) 
the papilla in the duodenum, thus mostly excluding tumours originating in the pancreatic tissue  
itself 8.  
Since the disagreement in terminology is considerable, and to avoid further confusion, we decided to 
completely avoid the term periampullary tumours. In the present thesis adenocarcinomas originating 
from the ampulla of Vater, the distal bile duct, the periampullary duodenum and the pancreatic head 
tissue itself are denoted pancreatic head adenocarcinomas. 
 
5.2.2 Pancreatic cancer  
Pancreatic adenocarcinoma is the fourth leading cause of cancer death in men and woman in western 
societies, with 5-year survival of less than 5% 9. The outcome of pancreatic cancer has remained 
largely unchanged for over the last three decades despite vast improvement in understanding of the 
biological and the clinical aspects of the disease, and improvement in the surgical and medical care.  
Adenocarcinoma of the pancreas is characterized by a high prevalence of genetic alterations, a 
propensity to metastasize at a very early stage, and a general resistance to conventional chemotherapy 
and radiation therapy10;11. 
Molecular studies on pancreatic adenocarcinomas have revealed a number of genetic alterations, 
which involve activation of K-ras, inactivation of p53 and p16, and deregulations of growth factors or 
growth factor receptors12. The genetic alterations have also been identified in precursor lesions of 
pancreatic cancer12;13. The transformation of normal duct epithelial cells into invasive 
adenocarcinoma is believed to be gradually developed through formation of lesions that initiates 
diverse changes in the morphology and functions of the cells. The most common neoplastic 
precursors to invasive adenocarcinoma are pancreatic intraepithelial neoplasia (PanIN), mucinous 
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cystic neoplasm (MCN) and intra-ductal papillary mucinous neoplasm (IPMN). PanIN development 
may be separated into 3 stages, beginning with ductal cell hyperplasia (PanIN-1A and 1B), followed 
by atypical hyperplasia ( Pan IN-2), and the formation of high grade dysplasia ( PanIN-3)14;15. The 
latter is frequently present adjacent to pancreatic adenocarcinoma on histopathological examination 
of resected specimens. MCNs are composed of mucin- producing epithelial cells with a distinctive 
ovarian type stroma and may also progress to invasive adenocarcinoma16. IPMNs are large mucin- 
secreting neoplasms, which may progress to either mucinous non – cystic (colloid) carcinoma or 
ductal adenocarcinoma13;17;18.  
The incidence of pancreatic cancer is strongly age-dependent. The peak incidence of the disease is in 
the seventh to eighth decades of life, and most cases (80%) occur between the ages 60 and 80 years.  
Cigarette smoking has been consistently identified as one of the strongest risk factors, which is 
thought to be involvement in as much as 15-30% of all cases19;20. A number of dietary factors are also 
considered associated with pancreatic cancer. High intake of fats, nitrates, meat, dairy products and 
high total energy intake and general obesity ( BMI ≥30 kg/m2) have all been shown to be associated 
with increased risk of PC21. Furthermore, it is generally accepted that patients with longstanding 
diabetes mellitus (type II), have a two-fold increased risk of developing PC22. 
Results from the studies which examined alcohol consumption, coffee habits and chronic pancreatitis 
as possible risk factors have been contradictory and inconclusive19;23. Regular physical activity, diets 
high in fruits, vegetables, fiber and vitamin C appear to decrease the risk of developing PC21;24;25. 
In approximately 5-to10 percent of pancreatic cancer, various genetic factors are thought to be 
associated with the disease. The genetic disorders associated with an increased risk of pancreatic 
cancer include hereditary breast and ovarian cancer syndrome (BRCA-2), hereditary pancreatitis, 
familial atypical multiple mole melanoma (FAMMM) syndrome, Peutz-Jeghers syndrome, hereditary 
nonpolyposis colorectal cancer syndrome (HNPCC), and Li-Fraumeni syndrome14;26. However, these 
genetic disorders account for very few of the total number of patients who develop PC.   
 
5.2.3 Distal bile duct cancer 
Cholangiocarcinomas, as a whole, accounts for approximately 3% of all gastrointestinal cancers. 
Distal bile duct tumours arise between the junction of the cystic duct- bile duct and the ampulla of 
Vater, and account for 20% to 30% of all cholangiocarcinomas27,28. The likelihood of developing 
distal cholangiocarcinoma increases with age, with a peak in the seventh decade. There also tends to 
be a slight male predominance for these lesions.  
These tumours originate from cholangiocytes, the epithelial cell lining the bile ducts29. Most cases of 
cholangiocarcinomas are sporadic and without an identifiable cause. However, there are some 
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inflammatory condition involving the bile ducts, like primary sclerosing cholangitis (PSC)30, chronic 
stone disease31, choledochal cysts, Caroli disease and diverse infectious which may also initiate the 
development of these tumours.  
Recently, precursors lesions associated with development of cholangiocarcinoma have been 
described32;33. The main types are biliary intraepithelial neoplasia (BilIN) 1-3 and intraductal 
papillary neoplasm of the bile duct (biliary IPN).   
 
5.2.4 Ampullary cancer 
Adenocarcinomas in the ampulla of Vater are not very common, representing only 0.2% of all gastro-
intestinal cancers and accounting for 15-25% of neoplasms arising in the periampullary region5;6;34-39. 
These tumours typically have either intestinal or pancreatobiliary-type of histologic 
differentiation40;41. Most carcinomas of the ampulla of Vater develop sporadically, however they are 
often associated with pre-existing ampullary adenomas42. The peak age incidence of sporadic 
ampullary carcinomas is in the seventh and eighth decades of life and males appear to be more 
affected than females. Cigarette smoking has been discussed as a risk factor for development of this 
malignancy. Similarly to pancreatic and distal cholangiocarcinomas, ampullary carcinomas are also 
associated with several genetic alteration43-45. 
 
5.2.5 Periampullary duodenal cancer 
Primary malignant tumours of the duodenum represent 0.3% of all gastro-intestinal tract tumours but 
up to 50% of small bowel malignancies. The large majority of duodenal tumours are 
adenocarcinomas46. The tumours can be located in any part of the duodenum but the most frequent 
location is the descending part.  
The major duodenal papilla is situated in the second part of duodenum, about 7-10 cm from the 
pylorus. It is surrounded by the sphincter of Oddi, and receives a mixture of pancreatic enzymes and 
bile from the Ampulla of Vater which drains both the pancreatic and distal bile duct. 
The major duodenal papilla is seen from the duodenum as lying within a mucosal fold. The minor 
duodenal papilla is situated 2 cm proximal. Adenocarcinomas arising from the duodenal papilla are 
sometimes mistakenly regarded as the amullary carcinomas, while they represent the pure duodenal 
tumours 47. 
Adenocarcinoma of the duodenum may arise from duodenal polyps observed in familial polyposis or 
Gardener's syndrome, or be associated with celiac disease48;49. The 5-year survival rate varies widely 
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according to the series published, but is generally reported to be > 40% in case of curative resection. 
The peak of frequency is the sixth decade, although the disease may develop in younger patients.  
 
5.3 Treatment  
 
5.3.1 Surgical treatment 
Due to the complexity of the regional anatomy pancreatic, distal bile duct, ampullary and 
periampullary duodenal cancers are all resected by a common surgical procedure. Surgical resection 
is the only potentially curative therapy for most of those tumours; however, resection is frequently 
not possible due to locally advanced disease or distant metastasis. 
Thus at the time of diagnosis, only 10 to 20% of the tumours of the pancreatic head are surgically 
resectable and the number is even lower when the carcinoma is situated in the body or tail of the 
gland.   
The treatment of choice for a pancreatic head tumour is a pancreatoduodenectomy, which can be 
performed as  classical50 or pylorus-preserving51. The classical pancreatoduodenectomy, often 
referred to as a Whipple’s procedure, involves surgical removal of the pancreatic head, duodenum, 
the distal bile duct, the gallbladder, and the distal part of the stomach. In the pylorus-preserving 
pancreatoduodenectomy, the distal part of the stomach with pylorus is not removed. Both procedures 
are performed with similar morbidity and mortality52.  
The extend of lymphadenectomy during pancreatoduodenectomy has been a matter of discussion. 
Lymphadenectomy can be carried out as a standard or an extended procedure. Currently a standard 
procedure, including removal of the lymph nodes of the right side of the hepatoduodenal ligament, 
anterior and posterior pancreaticoduodenal nodes and nodes to the right side of the superior 
mesenteric artery as en bloc resection is recommended. Additional nodes of the anterior- superior 
region of the common hepatic artery are removed separately 53 (Fig.3). Radical or extended 
lymphadenectomy includes removal of the glands near the common and proper hepatic artery, celiac 
axis, right and left side of the hepatoduodenal ligament, around superior mesenteric artery and the 
inferior pancreaticoduodenal artery, and all lymph nodes of the anterolateral aspect of the aorta and 
of the inferior vena cava (Fig.3). Extended lymphadenectomy  is currently not recommended since no 
survival benefit is obtained and the complications rates are higher compared to standard 
lymphadenectomy54-56.  
Tumours located in body and tail of the pancreas are removed by a distal pancreatic resection. 
Regional lymphadenectomy with en bloc resection of the nodes along celiac axis, splenic artery, and 
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splenic hilum and along the inferior border of the body and tail of the pancreas, is recommended in 
these cases53.  
 
 
Figure 3  
Lymph nodes removed with a standard (yellow circle), or radical (blue circle) 
pancreatoduodenectomy. Modified from Kawarada et.a57l. 
 
5.3.2 Medical treatment  
In the majority of patient with pancreatic cancer, curative surgery is not an option, and chemotherapy 
remains the only treatment. Unfortunately, currently available chemotherapy in advanced pancreatic 
caner has very limited effect on disease survival and  is primarily aimed at palliating symptoms to 
ensure better quality of life58.   
Two chemotherapies are mainly used as the adjuvant and palliative treatment for the patients with 
pancreatic cancer, i.e. 5-Fluorouracil (5-FU) or Gemcitabine. Since its approval in 1997, Gemcitabine 
was found superior to 5-FU, and has been the standard first –line palliative treatment worldwide for 
patients with PC59.   
Until December 2007, national guidelines for pancreatic cancer in Norway did not recommend 
adjuvant treatment. As from 2008, adjuvant therapy with 5-Fluorouracil is recommended for eligible 
patients which are operated for pancreatic cancer with curative intent, regardless of R-status or N-
stage 60.  
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For the two other tumour types removed with pancreatoduodenectomy, ampullary and distal bile duct 
cancer, there are no national guidelines regarding adjuvant treatment after surgery. In the cases where 
lymph node metastasis are detected and /or R1 resection status is present, adjuvant chemotherapy, 
similar to chemotherapy in the pancreatic cancer, might be considered. Patients with duodenal cancer 
usually receive the same type of chemotherapy that is recommended for patients with colorectal 
adenocarcinoma61. 
 
5.4 Prognosis 
 
 
Long-term survival after pancretoduodenectomy varies substantially among adenocarcinomas derived 
from pancreas, distal bile duct, ampulla and duodenum (Table 1). There is also considerable variation 
in survival data within the individual tumour sites as reported in different series of 
pancreatoduodenectomy from European and American centres. It is especially prominent in 
pancreatic cancer where the 5-year survival varies from five to twenty percent. Although this 
variation might be at least partly explained by differences in selection of patients or dissimilar 
approach to surgical management, it also indicates problems with correct histopathological 
assessment of tumour origin. Tumours with “better prognosis” originating in Ampulla of Vater or 
duodenum might be mistakenly diagnosed as pancreatic cancer and thus causes a falsely favourable 
prognosis for pancreatic cancer in the survival analysis.  
 
5.5 TNM classification    
The classification of tumours in the pancreatic head removed by pancreatoduodenectomy is based on 
the TNM system, revised in 201066 (Table 2). In pancreatic cancer, the definition of T1 and T2 -status 
is linked directly to the size of the tumour within pancreas. In ampullary and distal bile duct invasion 
to the adjacent structures signifies T2 status. The pancreatic cancers however, regardless of size, are 
Table 1. The 5-year survival rate for patients operated with pancreatoduodenectomy for 
pancreatic, distale bile duct, ampullary and duodenal adenocarcinoma 
Pancreatic 
cancer5;38;62-65 
Distal Bile Duct 
Cancer5;38;62-65 
Ampullary 
cancer5;38;62-65 
Duodenum 
cancer5;38;65 
5-20% 13-53% 35-54% 44-59% 
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classified as T3 tumours when they extend beyond the pancreas without affecting the celiac trunk or 
the superior mesenteric artery.  
Pancreatic cancer Distal bile duct cancer Ampullary cancer Duodenal cancer
T-status
T1 Tumour limited to pancreas,    2 cm or less in dimension
Tumour confined to the bile 
duct histologically
Tumour limited to ampulla of 
Vater of sfincter Oddi
Tumour invades lamina propria 
or/and submucosa
T2 Tumour limited to pancreas, more than 2 cm in dimension
Tumour invades beyond the 
wall of the bilde duct Tumour invades duodenal wall
Tumour invades muscularis 
propria
T3
Tumour extends beyond 
pancreas but without 
involvement of CA or AMS
Tumour invades gallbldder, 
pancreas, duodenum or othe 
adjacent organs without 
involvement of CA of AMS
Tumour invades pancreas
Tumour invades through the 
muscularis propria with 
extension 2 cm or less
T4 Tumour inviolves CA or AMS   (unresectable primary tumour) Tumour involves CA or AMS
Tumour invades peripancreatic 
soft tissues or other adjacent 
organs or structures other than 
pancreas
Tumour perforates the visceral 
peritoneum with extension 
more than 2 cm and/or invades 
pancreas or bile duct
N-status
N0 No regional node metastasis No regional node metastasis No regional node metastasis No regional node metastasis
N1 Regional node metastasis Regional node metastasis Regional node metastasis Metastasis in 1to 3 regional lymph nodes 
N2 Metastasis in 4 or more regional lymph nodes 
M-status
M0 No distant metastasis No distant metastasis No distant metastasis No distant metastasis
M1 Distant metastasis Distant metastasis Distant metastasis Distant metastasis
Table 2. TNM classfication 201061 
CA - celiac axis
AMS - arteria mesenteric superior  
 
5.6 Lymph node status  
TNM staging forms the basis for estimation of the prognosis of gastrointestinal epithelial 
malignancies.  In most studies, tumour size and the nodal status are the most important predictors of 
prognosis. According to current AJCC guidelines, adequate staging of node-negative pancreatic 
cancer requires evaluation of minimum 12 lymph nodes, although N0 is assigned even when this 
number is not met as long as all evaluated lymph nodes are found negative67. 
Recent publications have called attention to the ratio of positive (metastatic lymph nodes) to resected 
lymph nodes (total yield of resected nodes) as a negative prognostic factor68. The ratio of these two 
values is called the lymph node ratio (LNR). LNR may improve discrimination between prognostic 
groups by taking into account the extent of metastatic disease (number of positive nodes), as well as 
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the adequacy of lymphadenectomy and its histopathologic analysis (total number of nodes removed 
and identified in the surgical specimen). As LNR may to some degree compensate for variations in 
surgical and pathological node dissections it has therefore been proposed as an alternative measure of 
nodal involvement in adenocarcinomas of the pancreatic head68.  
 
5.7 Stellate cells, tumour stroma  
A particular feature of primary pancreatic adenocarcinoma is the extensive fibrotic stromal reaction 
surrounding these tumours, known as tumour desmoplasia. Numerous lines of evidence suggest that 
pancreatic stellate cells (PSC) have a major role in the development of fibrosis associated with 
chronic pancreatitis and pancreatic cancer69-72.  
PSC are resident cells in the exocrine pancreas, comprising approximately 4-7% of the total cell mass 
of the gland73;74. The cells are located adjacent to the basolateral aspect of pancreatic acinary cells. In 
a healthy gland, PSC are in their quiescent state, characterised by abundant vitamin A storing lipid 
droplets in the cytoplasm and showing a “star” shaped morphology73. They can be differentiated from 
fibroblasts due to expression of desmin, glial fibrillary acidic protein (GFAP), nestin and neural cell 
adhesion molecule. PSC play an important role in normal extracellular matrix (ECM) turnover via 
their ability to both synthesize and degrading matrix molecules69-72.
Upon activation, in response to injury, inflammation, or in culture, the PSC loose their vitamin A 
droplets and assume a myofibroblasts-like phenotype, express the cytoskeletal protein α-smooth 
muscle actin (αSMA) and synthesize excessive amounts of extracellular matrix proteins leading to 
fibrosis (Fig. 4). 
         a.      b. 
 
 
 
  
Figure 4. Activated pancreatic stellate cells in culture. a. large amount of extracellular matrix 
proteins b. expression of the cytoskeletal protein α-smooth muscle actin (αSMA) 
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Histological and immunohistochemical studies of human pancreatic cancer have shown that activated 
PSC are present and are responsible for producing the stromal reaction in the desmoplastic areas of 
pancreatic cancer75. Studies of human and rat PSC in culture have identified a number of growth 
factors, cytokines, and hormones as regulators of pancreatic stellate cell activation 70. Platelet-derived 
growth factor (PDGF)76, transforming growth factor-ß   (TGFß)70;77, interleukin -1 ß (Il-1ß)78 and 
epidermal growth factor (EGF)79 are some of the factors which regulate proliferation, activation, 
collagen production and apoptosis in the pancreatic stellate cell. 
The effects of cyclooxygenase -2 (COX-2) and its product prostaglandin-E2 (PGE2) are widely 
studied in fibroblasts, mainly in lung and liver. In the lung, PGE2 has the ability to limit fibroblast 
proliferation and migration and has been found to inhibit collagen synthesis by activating EP2 
receptors and stimulating cAMP accumulation80. In patients with idiopathic pulmonary fibrosis, lung 
fibroblasts display low capacity to express COX-2 and to synthesize PGE2 resulting in fibroblast 
accumulation and relentless deposition of collagen81-83. In the liver, PGE2 via the cAMP pathway 
negatively regulates the proliferative effect of growth factors on hepatic stellate cells84.  Thrombin 
and PDGF stimulate the release of PGE2, which again exerts an inhibitory effect on DNA synthesis 
induced by PDGF and thrombin. Although the functions of prostaglandin E2 ( PGE2) are well defined 
in lung and liver, its influence on the functions of the pancreatic stellate cells, particularly the effects 
on pancreatic fibrosis and cell proliferation, is still uncertain.  
Several lines of evidence suggest that in pancreatic cancer, PSC are of great importance for tumour 
progression, by interacting in many ways with the malignant cells, such as reciprocal paracrine 
proliferative stimulation and angiogenesis, contributing to the early invasive growth and metastasis of 
this tumour70;71. Coculture experiments with PSC and pancreatic cancer cell lines confirm these 
findings, showing that exposure of PSC to cancer cells either directly or via conditioned media results 
in activation of PSC and consequently increased proliferation, ECM synthesis and migration71.  In 
turn, PSC stimulate cancer cell proliferation and inhibit cancer cell apoptosis85 ( Fig. 5). 
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Figure 5. Bidirectional interactions between pancreatic cancer cells and stellate cells  
 
 
 
 
5.8 COX-2 
 
Cyclooxygenase (COX) is a rate limiting enzyme involved in the conversion of arachidonic acid into 
prostaglandin H2, which represents a precursor of several bioactive molecules, including 
prostaglandin E2, prostacyclin, and tromboxane86 (Fig. 6). Two different isoenzymes, COX-1 and 
COX-2, have been identified87. There has also been reported a third isoform of COX enzyme, COX-3, 
which is a splice variant of COX-1, thus by some named COX-1b or COX-1 variant (COX-1v)88.  
COX-1 is constitutively expressed in many tissues including kidney, lung, stomach, duodenum, 
jejunum, ileum, colon and coecum89. COX-1 exerts diverse physiological functions such as 
maintaining gastric mucosa, platelet aggregation, maintenance of renal blood flow, glomerular 
filtration and ovulation90,91.  
 21 
 
Figure 6. Production of prostaglandins and other eicosanoids. Tissue damage causes arachidonic 
acid to be split off the cell membrane phospholipids. There are two main pathways; the lipoxygenase 
pathway leads to the formation of leukotrienes and lipoxins, whereas the COX pathway leads to 
formation of prostaglandins and thromboxanes. 
 
COX-2 expression is normally absent in the majority of tissues, however it can be induced in 
response to several intra- or extracellular stimuli, including proinflammatory cytokines, infectious 
agents, mitogens, hormones, and growth factors90;92;93. COX-2 overexpression has also been 
described in several tumours, including cancers derived from colon94;95, breast96;97, urinary bladder98, 
lung99;100, stomach101 and pancreas102-108.  
The role of COX-2 in carcinogenesis has been investigated most extensively in colonic neoplasia, 
especially in patients with familial adenomatous polyposis.  The results, from most of the studies, 
indicate a correlation between high COX-2 expression and poor prognosis in colonic cancer109;110.  
 
5.8.1 COX-2 in pancreatic head adenocarcinomas  
Although several studies showed a potential involvement of COX-2 in tumorigenesis and an inverse 
relationship between COX-2 overexpression and survival rates in malign tumours, results from 
studies of COX-2 ekspression in tumours located in the pancreatic head are inconsistent.  
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It is generally acknowledged that COX-2 expression is upregulated in pancreatic cancer 
cells102;103;105-108;111;112. However, how or if COX-2 promotes pancreatic cancer development is still 
unclear. Many studies show either no relation or positive correlation between COX-2 expression and 
favourable clinicopathological parameters or survival 103;104;106;107;111-116. In particular, high 
differentiation grade was frequently associated with increased COX-2 expression106;107. Other 
publications demonstrate negative effect of COX-2 expression on survival102;105. 
There are also contradictory reports on the use of non-steroidal anti-inflammatory drugs in pancreatic 
cancer. In some studies, an association between prolonged use of COX-2 inhibitors and increased risk 
of PC was observed117;118, while other studies showed the opposite effect119. Some other, 
experimental studies proposed a dual, both stimulating and suppressing effects of COX-2 inhibitors, 
depending on the degree of COX-2 expression in tumour cells, and the dose of COX-2 
inhibitors120;121. 
There are only few publications reporting COX-2 expression in ampullary and distale bile duct 
carcinoma122-127. Although the experimental data on cell lines suggest that COX-2 may play a role in 
carcinogenesis, angiogenesis or apoptosis128;129, there is no data indicating an association between 
COX-2 and survival in these two types of carcinoma.  One study reported a shorter median survival 
in patients with COX-2 positive ampullary carcinomas, however, in this study node metastasis 
showed no effect on survival, suggesting that the studied patient group might not have been properly 
selected127. The association between COX-2 expression and type of differentiation have been studied 
in ampullary carcinoma125 and the results demonstrated a high rate of COX-2 expression in the 
intestinal subtype (92%). The clinical significance of those results was not established, however, a 
significant negative correlation was found between T stage and COX-2 expression125.  
 
5.9 PGE2 
Most cellular effects of COX-2 are performed via its metabolite prostaglandin E2 (PGE2). 
PGE2 exerts its cellular effect through G-protein- coupled EP and FP receptors 130;131.  The functions 
of the EP receptors are dictated by the intracellular signalling machinery coupled to each receptor. 
EP2 and EP4 receptors are Gs-coupled receptors that stimulate adenylyl cyclase activity. This results 
in an increase of cyclic adenosine monophosphate (cAMP) - the second messenger that has influence 
on many aspect of cellular function, from differentiation to cell death132.  EP3 receptors are Gi-
coupled receptors that inhibit adenylyl cyclase activity with subsequent decrease in intracellular 
cAMP. EP1 receptors elevate the intracellular Ca2+-levels through mechanisms that may involve both 
phospholipase C-dependent and -independent mechanisms 130;131;133, and FP receptors are Gq-coupled 
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receptors that elevate intracellular Ca2+-levels 130;131. In addition, several of these receptors may 
signal via G protein-independent mechanisms 134.   
Elevated COX-2 and its metabolite PGE2 are associated with a wide range of effects, including 
cellular proliferation, differentiation, angiogenesis and apoptosis80;84;135-140. 
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6. Aims of the study 
The aims of the present study were to investigate how the standardized histopathological examination 
protocol can help to correctly classify the tumour origin of pancreatic head adenocarcinomas. Further, 
we examined how different approaches to assessment of lymph node metastases and expression of 
COX-2 in the tumours can predict long-term outcome. Finally we assessed COX-2 expression and 
effects of PGE2 on cells proliferation and collagen synthesis in pancreatic stellate cells in vitro. 
 
The specific aims of this study were: 
1. How does predetermined diagnostic criteria and the experience of the pathologists involved in the 
histopathological evaluation influence the accuracy of diagnosis of pancreatic head 
adenocarcinomas?  
 
2. What is the best prognostic factor for long-term survival for pancreatic head adenocarcinomas,  
N status, lymph node ratio (LNR), or the actual number of metastatic lymph nodes? Do these 
different measures of lymph node metastasis discriminate differently between prognostic subgroups 
among the three types of pancreatic head cancers?     
 
3. What is the prevalence of COX-2 expression in tumour tissue of pancreatic head adenocarcinomas, 
as assessed by immunohistochemistry? Does COX-2 expression have any prognostic relevance? Are 
there any other prognostic factors associated with COX-2 expression?  
 
4. Which cells in pancreatic cancer tissue express COX-2? Specifically, how is COX-2 expression in 
the pancreatic stellate cells regulated and what is the role of PGE2? 
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7. Summary of results 
Paper I  
Reclassification of tumour origin in resected periampullary adenocarcinomas reveals 
underestimation of distal bile duct cancer 
Eur J Surg Oncol 2012; 38:1043-1050. 
 
Primary adenocarcinomas removed by pancreatoduodenectomy originate from the duodenum (DC), 
ampulla (AC), distal bile duct (DBC), or pancreas (PC). Despite the well-established histological 
definition of the anatomical structures in the specimen, the precise tumour origin may be difficult to 
determine, especially when the tumour is large and involves more than one anatomical position. 
Correct diagnosis is essential for appropriate adjuvant therapy, patient inclusion in clinical trials, and 
the general quality of the clinical data.  
In this study, routine histopathology reports of tumour origin performed by multiple pathologists 
were independently re-evaluated by two experienced pancreatic pathologists, based on predetermined 
criteria.  
We found that slide review changed the diagnosis in 27% of the patients. Distal bile duct cancer was 
found to be most frequently misdiagnosed. Misclassification of PC was mainly due to erroneous 
diagnosis of AC. Reassignment of tumour origin caused no significant changes in survival within 
cancer type, but resulted in a significant difference in survival between DBC and PC. 
These results indicate that standardised histopathological evaluation based on predetermined criteria 
and performed by experienced pathologists can improve accuracy of the diagnosis.  
 
Paper II 
Prognostic relevance of number and ratio of metastatic lymph nodes in resected pancreatic, 
ampullary and distal bile duct carcinomas                                                                                     
Ann Surg Oncol 2013; 20:233-241 
In this study we evaluated how N status, lymph nodes ratio ( LNR) and number of metastatic lymph 
nodes predict long- term survival after pancreatectomy for ampullary (AC), biliary (DBC), and 
pancreatic (PC) adenocarcinomas. We show that lymph node involvement was more frequent in PC 
than in AC and DBC. 
Our results demonstrate that the prognostic value of nodal involvement depends on the cancer origin. 
In AC and DBC, N status clearly discriminates between subgroups of patients with different long-
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term survival, whereas number of metastatic nodes and LNR do not predict survival among node-
positive resections. In PC, N status does not discriminate between prognostic groups. However, 
increasing LNR is significantly associated with poorer survival both in unadjusted analysis, as well as 
when adjusting for margin involvement, degree of differentiation, and tumour diameter. In addition, 
the data demonstrated that LNR is more predictive of long- term outcome when the number of lymph 
node assessed is insufficient.  
 
Paper III 
COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favorable 
prognosis 
BMC Cancer 2014; 14:458  
Overexpression of cyclooxygenase-2 (COX-2) has been implicated in oncogenesis and progression of 
adenocarcinomas of the pancreatic head. The data on the prognostic importance of COX expression 
in these tumours is inconsistent and conflicting. In this paper we evaluated how COX-2 
overexpression affected overall postoperative survival in pancreatic head adenocarcinomas. COX-2 
immunohistochemistry was performed on whole tumour slice.  
Our results demonstrate that COX-2 is overexpressed in pancreatic cancer, ampullary cancer and 
distal bile duct cancer and confers a survival benefit in all three cancer types. The overexpression is 
consistently linked to the histopathological type of differentiation and to the degree of differentiation. 
Moreover, in pancreatic cancer, COX-2 independently predicts a favourable prognosis.  
 
Paper IV 
Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human 
stellate cells from pancreatic head adenocarcinoma. 
BMC Cancer 2014; 14:413 
 
Several studies have described an increased cyclooxygenase-2 (COX-2) expression in pancreatic 
cancer, but the role of COX-2 in tumour development and progression is not clear.  The aim of the 
present study was to examine expression of COX-2 in cancer cells and stromal cells in pancreatic 
cancer specimens, and to explore the role of PGE2 in pancreatic stellate cell proliferation and 
collagen synthesis. 
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We performed immunohistochemistry and immunofluorescence on slides from whole sections of 
tissue blocks using antibodies against COX-2 and α-smooth muscle actin (αSMA). Pancreatic stellate 
cells (PSC) were isolated from surgically resected tumour tissue by the outgrowth method.  
Our results show that COX-2 is present in pancreatic carcinoma cells, but not in stromal cells. 
Cultured PSC however express COX-2, which can be further induced by interleukin-1β (IL-1β), 
epidermal growth factor (EGF), thrombin, and PGE2, but not by transforming growth factor-β1 
(TGFβ). Indirect coculture with the adenocarcinoma cell line BxPC-3, but not HPAFII or Panc-1, 
induced COX-2 expression in PSC.  
We further showed that treatment of PSC with PGE2 strongly stimulates cAMP accumulation, 
mediated by EP2 receptors, and also stimulates phosphorylation of extracellular signal-regulated 
kinase (ERK).   Treatment of PSC with PGE2 or forskolin suppresses both TGFβ-stimulated collagen 
synthesis and PDGF-stimulated DNA synthesis.  
Our results demonstrate that COX-2 is mainly produced in carcinoma cells and suggest that the 
cancer cells are the main source of PGE2 in pancreatic tumours. PGE2 exerts a suppressive effect on 
proliferation and fibrogenesis in pancreatic stellate cells. These effects of PGE2 are mediated by the 
cAMP pathway and suggest a role of EP2 receptors. 
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8. Discussion 
 
8.1 Methodological consideration 
 
8.1.1 Patient selection 
The patient groups included in the present study comprised individuals who underwent a standard 
pancreatoduodenectomy (Whipple’s procedure) for pancreatic head adenocarcinoma between 1998 
and 2011 at Oslo University Hospital, Rikshospitalet. 
The study protocol and patient consent documents were approved by the Regional Committee for 
Medical and Health Research Ethics, and was in compliance with the Helsinki Declaration. The study 
included only adults. Since all Norwegian inhabitants receive a unique personal identification number, 
it is possible to trace information about death date for nearly all citizens. In the presented study, no 
patients were lost to follow-up. For survival studies, patients were followed until death or censored 
after maximum five years (60 months). 
Hospital records were reviewed retrospectively, and standard demographic, clinicopathological, and 
tumour-specific data were collected. 
Patients included in the study were operated with curative intent for primary adenocarcinomas in the 
pancreatic head, including ampullary adenocarcinoma (AC), distal bile duct adenocarcinoma (DBC) 
and pancreatic adenocarcinoma (PC).  
Paper I and II included 179 patients operated between 1998 and 2009. For the purpose of data 
presented in the paper I, 28 patients with diagnosis of the adenocarcinoma of the periampullary 
duodenum (DC) operated during the same period, were also included.  
In paper III, patients with diagnosis AC, DBC or PC operated during 2010-2011 were also included 
giving a total of 230 patients studied..  
Overall in this thesis, 261 consecutive pancreatoduodenectomies for PC 92 (35%), AC 62 (24%), 
DBC 76 (29%) or DC 31 (12%) operated during 1998-2011 were studied. 
 
8.1.2 Histopathological assessment 
Most of the resection specimens (230) were routinely handled with the bisectional dissection 
method141  and examined  according to a standardised protocol as described by Westgaard at al. 142. 
After introduction of the axial slicing method143 in 2010, 31 consecutive pancreatoduodenectomy 
specimens were handled according to this new technique.   
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The following histopathologic factors were prospectively registered in routine practice: tumor origin, 
type of differentiation, maximum tumour diameter, degree of differentiation, perineural infiltration, 
vascular infiltration, ductal dysplasia, lymph node status, and resection margins involvement. For 
identification of the anatomical origin of the tumour, blocks were made by sectioning parallel to these 
structures and including the duodenum and ampulla of Vater, in order to demonstrate the relation of 
the tumour to these structures. As from 2003, in the majority of cases whole mount blocks were made 
for identifying the relation of the tumours to the critical structures. If necessary, further cross sections 
of the tumour were made to evaluate tumour size and infiltration into adjacent structures.  
 
The primary histopathological evaluation was performed by different pathologists involved in the 
routine evaluation. As many of them were not attached permanently to the pancreatic unit at the 
Department of Pathology, the number of examinations of the present material performed by a single 
pathologist varied between two and 68. The four pathologists with the highest workload together 
assessed 87% of the total cohort. In the routine assessment of tumour origin pathologists followed 
generally established guidelines. However, due to different level of experience of the pathologists 
involved, the quality and accuracy of the assessment varied among assessed cases.  
 
8.1.2.1 Tumour origin 
In all cases retrospective reevaluation of the cancer origin was performed.  
All registered parameters of the prospectively collected database, including anatomic site of tumour 
origin, were independently reevaluated by slide review performed by an experienced gastrointestinal  
pathologist (OPFC). In paper I, due to the study design, additional reevaluations were also performed 
by another experienced pathologists (KG). Both pathologists were also involved in the primary, 
routine assessment of the specimens.  
During reevaluation of tumour origin, the two pathologists followed the general guidelines also used 
under routine evaluation. The main criteria included estimation of the centre of the tumour mass, 
tumour location relative to ductal, duodenal and pancreatic anatomy, and the presence of epithelial 
dysplasia or in situ neoplasia. In large tumours, cancer infiltration located at both sides of the bile 
duct and /or presence of BilIN were generally considered to indicate bile duct origin. Presence of 
PanIN in the pancreatic duct or dysplasia in the ampulla suggested pancreatic or ampullary origin, 
respectively. Extension and location of the central tumour mass also played an important role in the 
final evaluation of the site of tumour origin. Many duodenal/papillary tumours showed extension into 
the ampulla, and, conversely, ampullary tumours could affect the duodenum, rendering many of these 
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tumours difficult to classify. In these cases extension of in situ alterations and location of the central 
tumour mass were taken into account.  
Following the independent reassessment by the two expert pathologists, cases that had been assigned 
to different locations were identified, and subjected to further discussion for obtaining a consensus 
decision, which thus constituted the final classification. All tumours were allocated to one of the 
following locations: duodenum, ampulla, distal bile duct or pancreas.  
Upon slide review, the two pathologists were blinded to the original diagnosis. The clinical and 
macroscopic data were available, as had been the case during the primary evaluation. 
 
8.1.2.2 Lymph node assessment 
Pancreatoduodenectomy without radical lymph node resection was performed in our hospital as a 
standard procedure. Lymph nodes were obtained by en bloc dissection of primary metastatic regions, 
not including secondary sites such as the peri-aortic lymph nodes39-42 (Figure 3). 
Nodal status was registered prospectively by routine pathologists according to the standardized 
protocol. Numbers of positive and total lymph nodes were extracted from the pathology reports, and 
LNR was calculated according to these numbers. The present study did not discriminate between 
nodal involvement due to direct invasion or true metastasis, in accordance with recommended 
principles for staging of nodal involvement144. 
 
8.1.3 Immunohistochemistry 
 
In Paper III, COX-2 expression in the tumours of the pancreatic head was evaluated by 
immunohistochemistry. Monoclonal COX-2 antibodies were applied to 230 whole tumour sections. 
Prior to the final immunostaining, multiple testing of buffer type and antigen dilutions was performed. 
The optimal antibody dilution was established as 1:25. 
For each batch of tumour sections to be stained, positive and negative control were determined. Islets 
of Langerhans and/or duodenal mucosa were moderately to strongly positive for COX-2, also in 
those tumours with no COX-2 expression, and served as internal positive controls. Additionally, 
sections with omission of the primary antibody were used as negative controls.  
To test the validity of the Thermo antibody used for the study cohort, we performed additional 
immunostaining with a different monoclonal COX-2 mouse antibody, Invitrogen (Camarillo, CA, 
USA), on duplicates of twenty pancreatic cancer slides from the study cohort.  The results of Thermo 
and Invitrogen immunohistochemistry were identical (Paper III, Fig.1e). As the Thermo antibody was 
 31 
not suitable for western blotting (producer recommendation), further validations of the 
immunochemistry by western blotting was performed only with the Invitrogen antibody.  The results 
showed a highly specific band for COX-2 (Paper III, Fig.1f).   
 
8.1.3.1 Evaluation of COX-2 immunostaining 
Since COX-2 expression in pancreatic tumours often is heterogeneous 104;111;145, the actual number of 
COX-2 positive tumours might easily be underestimated if tissue microarrays are used. In our study 
immunohistochemistry was therefore performed on whole slide sections and assessed on multiple  
high-power fields within each tumour.  
The COX-2 expression was evaluated by the intensity and the extension of staining. Tumours with 
moderate and strong staining were considered positive while tumours with no or faint staining were 
regarded as negative. COX-2 staining showed considerable heterogeneity within the tumours. Thus, 
the final immunoscore of COX-2 expression was calculated as an average of five different extension 
scores in the tumours considered positive on the intensity evaluation.  
To ascertain the reliability of the interpretation of the immunostaining, almost half of study 
specimens (44%) were tested for the interobserver variability with respect to scoring of the stained 
tumours. A kappa-value of 0.73 ( substantial agreement) was found. 
 
8.1.4 Isolation of pancreatic stellate cells  
 
One of the characteristic histological feature of pancreatic cancer is the prominent fibrosis 
surrounding the cancer cells. There is increasing evidence that pancreatic stellate cells are playing a 
critical role in this extensive stromal reaction known as tumour desmoplasia. To study the role of 
pancreatic stellate cells and particularly the effects of COX-2 and PGE2 on their proliferation and 
collagen production, we isolated and cultured pancreatic stellate cells from patients with resectable 
pancreatic head adenocarcinoma. 
Small tumour samples for isolation of the human pancreatic stellate cells were obtained during 
pancreatic surgery from patients operated in the period 2009 - 2011. All samples were coded to 
protect the identities of the subject participating in this study. The study protocol and patients consent 
documents were approved by the Regional Committee for Medical and Health Research Ethics, and 
complied with the Helsinki Declaration. 
 
 
8.1.4.1 Cell isolation and culture 
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Two main methods have been developed in recent years for isolation of pancreatic stellate cells. The 
isolation of quiescent PSCs from rat pancreas, using a centrifugation method, was first developed by 
Apte et al73.  This method was based on the density gradient caused by the presence of the lipid 
content in the stellate cells in their quiescent state.  
However, this method was not suitable for isolation of human pancreatic stellate cells from resection 
specimens from patients operated for pancreatic adenocarcinoma. Firstly, the available amount of 
tissue was strictly limited, both by the tumour size itself, and by demands from pathologist for routine 
diagnostics. Only when the pathologist had secured what was considered a sufficient amount of tissue 
for histological diagnosis, surplus tissue could be excised from the specimen for research purposes. 
As the amount of tissue might be very sparse, the centrifugation method of Apte at al73 was not easy 
to perform. The other main problem was the activation state of the stellate cells. As stellate cells 
become activated, which is the case during changes in the pancreas caused by cancer, they were 
losing lipid droplets, and the centrifugation method might fail. The last problem was the vast fibrotic 
reaction in the tissue form the pancreatic adenocarcinoma, which made it difficult to digest it 
properly prior to the centrifugation146. 
Bachem et al.74  described a different method for isolation of pre-activated human PSCs from 
resected tissue. This so-called outgrowth method of Bachem was used in our laboratory for the 
present study. Briefly, pancreatic tissue blocks (100–150 mg) were obtained during pancreatic 
surgery from patients with resectable pancreatic head adenocarcinoma. The tissue blocks were cut 
using a razor blade (0.5–1 mm3) and seeded in uncoated culture wells. Cells were cultured at 37˚C in 
5% CO2 / air humidified atmosphere. After reaching confluence, monolayers were trypsinized and 
passaged 1:3. The purity of the cells was assessed by morphology (most cells were stellate-like, with 
long cytoplasmatic extensions; some were also spindle shaped) and cytofilament staining of α-SMA 
and Vimentin (Fig.7). 
All experiments were performed using cell populations between passage 4 and 8. 
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Figure 7. Cultured pancreatic stellate cells. Cells are stellate-like, with long cytoplasmatic extension 
and have cytofilament staining of α-SMA and Vimentin. None of the cells are positive for cytokeratins 
7 or 19 characteristic for ductal adenocarcinomas 
 
 
 
The cultured pancreatic stellate cells were assessed after different passages with immunofluorescence 
staining with αSMA and COX-2.  (Fig.8)  
 
 
 
 
Figure 8.  Immunofluorescence staining of cultured 
pancreatic stellate cells, passage five; COX-2 positive cells 
- red colour, αSMA positive cells - green colour, nucleus -
blue colour. 
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8.2 Discussion of results 
 
In this thesis, we assessed the accuracy of the histopathological assignment of exact anatomical site 
of origin in the tumours of the pancreatic head (Paper I). Furthermore, we studied standard 
prognostics factors and proposed new variables as the predictors for long-term survival for patient 
operated with pancreatoduodenectomy for adenocarcinomas in this region. The included papers 
(Paper II and III) demonstrate particularly the impact of lymph node status, LNR and COX-2 
expression on prognosis. Lastly, in Paper IV, we studied PGE2 effects on pancreatic stellate cells.  
 
8.2.1 Tumour Origin 
Adjuvant treatment strategies and long-term survival differ considerably among the different types of 
adenocarcinomas in the pancreatic head. Failure to obtain a correct diagnosis leads to negative effects 
for the individual patient as the organ of origin determines inclusion in current postoperative adjuvant 
therapy regimens. For clinical trials on adjuvant treatment where tumour origin is the essential 
inclusion criterion, incorrect diagnosis may lead to false assumptions regarding the effectiveness of 
the therapy being given.  
Although the importance of the correct diagnosis is widely accepted, several lines of evidence 
suggest that the distinction between pancreatic, ampullary, distal bile duct and duodenal cancer, in 
series of pancreatoduodenectomies, might not always be reported in an accurate manner. Firstly, a 
reported relative incidence of the four cancer types in the several large European and American 
centres show large wide variation, which can not be explained solely by patient selection, and might 
cast doubts on the diagnosis precision5;6;34-37;39;143;147;148. Furthermore, several studies on the reported 
long – term survival after pancreatoduodenectomy directly question the accuracy and precision of the 
histopathological diagnosis149-151. Relatively high frequency of PC diagnosis combined with 
comparatively low frequency of the AC and DBC diagnoses in many series, might indicate that PC 
can be a default diagnosis, especially when histological assessment is particularly difficult5;6;34-
37;39;143;147;148. This results in extensive variation in the incidence of PC diagnosis, which varies from 
38% to 76% in different series of pancreatoduodenectomies 5;6;34-37;39;143;147;148. 
 
In this thesis, for the first time in a structured manner, we critically assessed the routine classification 
of tumour origin and investigated different aspects of the histopathological evaluation (Paper 1).  
The study demonstrates that slide review performed by experienced pancreatic pathologists with 
particular emphasis on determining the tumour origin based on predefined criteria is necessary for 
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correct assignment of tumour origin. The experience of the pathologists, and their attitude and efforts 
spent to determine the true tumour origin, was found to be more important than particular differences 
in specimen dissection, like the number of tissue block examined from each tumour or whether whole 
mount blocks were made or not.  
The most experienced pathologists, with the highest numbers of histopathological examinations, 
generally had fewer reclassified cases compared to the less experienced pathologists. This is probably 
a general phenomenon and not only limited to pathologists in Norway. A survey performed in the 
United Kingdom showed that only 20% of the pathologists actively distinguish DBC from PC, 13% 
reported that thy did not do so usually, while the remaining 67% reported that they just tried to make 
distinction152;153.  
As histopathological assessment of tumour origin in pancreatoduodenectomies is demanding, it 
should be noted that generally accepted international consensus guidelines regarding  recommended 
slicing techniques and assessment of tumour sections are still lacking152;153. 
The recently introduced technique of axial slicing has generally been shown to be superior to the 
bisectional technique143.  
After the completion of Paper I, we have introduced this method in our institution and the 31 
consecutive pancreatoduodenectomies were handled according to this technique.  
The conclusions of the study in Paper I and the introduction of method of axial slicing have increased 
the precision in establishing correct diagnosis in our department. At the end of the study period of 
261 specimens obtained during pancreatoduodenectomy, 230 specimens were handled with the 
bisectional technique, and 31 with axial slicing (Table 3). In the DBC group, the accuracy of the 
diagnosis of the tumour origin increased from 52% to 73%, in the PC group from 78% to 93%, and in 
the DC group from 87% to 100%. In the AC group the site of origin reminded generally unchanged 
(84 - 80%) presumably due to the small number of patients (5) where specimens were handled with 
the axial slicing method.  
Table 3. 
Bisectional slicing technique      
( 230 patients, 88%)
Axial slicing technique           
( 31 patients, 12%)
DBC 52 % 73 %
PC 78 % 93 %
DC 87 % 100 %
AC 84 % 80 %
Accuracy of the diagnosis 
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Although the number of cases assessed with the new technique was relative low 31 (12%), the results 
clearly showed that the combination of a new, better slicing technique with particular focus on 
correct tumour diagnosis among pathologists, could improve the quality of the histopathological 
evaluation. 
 
Taken together the study indicates that quality of the histopathological diagnostic work on pancreatic 
head tumours benefits from keeping this to experienced pancreatic pathologists in high- volume 
centres, just as what is now generally accepted for the surgical treatment of these tumours 154 
  
8.2.2 Prognostic factors in pancreatic head adenocarcinomas 
Since PC, AC, DBC and DC are separate cancer entities, different pathological variables may have 
different prognostic significance in these cancers. In paper II and III we assessed how lymph node 
status, lymph node ratio (LNR), and COX-2 expression may predict long-term survival in PC, DBC 
and AC. Tumours originated in the duodenum (DC), although removed by the same surgical 
procedure, are biologically and molecularly more related to tumours originated from the intestine 
(small bowel and colon) and were therefore excluded from this analysis. 
 
8.2.2.1 Evaluation of the nodal tumour involvement 
In the studies presented in paper II, we aimed to ascertain whether N status, number of metastatic 
lymph nodes or lymph node ratio (LNR) better predicts long- term survival after 
pancreatoduodenectomy for PC, DBC and AC. Previous studies that have approached this question 
have mostly been based on nonstandardized evaluation of the cancer origin3;143;150;154-156. In our 
studies, all results were based on tumour classification where the anatomic site of tumour origin had 
been subjected to reevaluation by slide review. This might at least partly explain the conflicting data 
as to which method is the better for the evaluation of nodal metastasis in adenocarcinomas arising 
from the separate anatomic locations (Table 2, Paper II).  
In the AC and DBC groups, lymph node involvement was significantly less frequent (48% and 57%, 
respectively) than in the PC group, where more than 75% of the patients had lymph node metastasis. 
In AC and DBC, nodal status distinctly predicted long- term survival, while LNR (among N1 
resections), was insufficient as a prognostic indicator.  
In the group of PC, there was no difference in overall survival between n N0 and N1 resections. This 
may be explained by the observation that there is no difference in long-term prognosis between 
patients with involvement of 0 or 1 lymph node (Paper II, Fig.2b). It is known that in some cases, 
involvement of one lymph node may be a consequence of direct lymph node invasion and thus not 
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representing true metastasis. The overall survival for these patients is similar compared to overall 
survival for patients with node - free resection157. However, in the current TMN system 
recommendation, all these patients are classified as N1158. The other possible explanation for the 
similar long-term survival of patients with no or one lymph node metastasis could be attributed to the 
aggressive biology of PC itself. The fact that the tumour originates from the pancreatic tissue is more 
biologically important than the presence of none or one lymph node metastasis3.  
In our study we provided evidence that in patients with pancreatic cancer diagnosis, LNR 
significantly discriminated between patients with good and poor prognosis, in the whole cohort of 
patients (N0 and N1 resections), and in patients with N1 resections alone.  
The optimal cut-off value of LNR is defined as the value that best stratifies patients with respect to 
cancer-specific survival. In our study, the LNR cut-point was defined as 0.2. In studies on LNR the 
cut-point used to determine patients group with different prognosis, has been between 0.15 and 
0.20159;160. A study of House161, specially designed to calculate the most optimal LNR cut-off, 
concluded that it might be 0.18. However, the mean number of evaluated lymph nodes in that study 
was 17, which is slightly higher than what is found in most other studies. The cut-off  point of LNR 
obviously depends on the average number of evaluated nodes159-161;161.  In our study, the median 
number of lymph nodes was eleven. The number was lower compared to the recommendation by 
AJCC162 (twelve nodes), however it was within the last recommendation from UICC (ten nodes)163. 
The median number of evaluated lymph nodes is most frequently ≤ 9 even in academic institutions164, 
A high lymph node yield could also in some reports result from resections involving extended 
lymphadenectomy165. The median number of lymph nodes evaluated in the present study is thus 
representative of a medium-volume tertiary referral institution. 
Taken together our results indicated that N status evaluation was sufficient and superior to LNR in 
nodal evaluation for AC and DBC. Those results were confirmed in multivariate analysis, where N 
status was an independent prognostic variable in AC and DBC.  
In PC, in contrast, N status was insufficient as a prognostic factor. Furthermore, in PC LNR was 
significantly associated with overall survival and thus serves as an independent predictor of long- 
term prognosis.  
Importantly, the finding that LNR is a better predictor of survival than node status or tumour size in 
PC raises the question whether standard TNM classification in pancreatic tumours could be extended 
to include LNR data. Since our study is limited by a relatively low number of patients, larger studies, 
where anatomic tumour origins are properly examined/determined, are needed to confirm these 
results.  
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8.2.2.2 COX-2 expression 
In Paper III, we assessed by immunohistochemistry, whether COX-2 expression predicts long-term 
survival in resected PC, DBC and AC. Our study is the first which compares COX-2 expression 
levels in these three types of cancer in a setting where the tumour origin has been determined by 
standardised histopathological evaluation. 
We found that COX-2 expression was very similar in all three tumour types, with positivity rate over 
70%. Overall patient survival was more favorable in COX-2 positive than COX-2 negative tumours 
in all tumour types (Paper III Fig 2 a-c). This was particularly prominent in AC and PC. In DBC the 
same trend was observed, however, not reaching significance.  
As the precise function of COX-2 in development of tumours in the pancreatic head is not fully 
understood, our results may contribute to elucidating some features of the tumours, including the 
association between histologic differentiation and COX-2 expression. 
Previous studies have shown that the histologic type of differentiation of tumours of the pancreatic 
head significantly influences patients’ survival155;166. Tumours with intestinal type of differentiation 
have generally a more favorable prognosis than tumour with pancreaticobiliar type155;166. When 
exploring the potential relationship between differentiation type and COX-2 expression, we found 
that all of the PC and DBC tumours, and over 80% of the AC with intestinal type of differentiation 
were COX-2 positive. The survival data of intestinal tumours in AC showed a particularly favorable 
prognosis for patients with tumours expressing COX-2. Taken together this confirms that COX-2 
expression in the tumours of the pancreatic head is closely related to the intestinal type of 
differentiation. As the survival of the patients with tumours exhibiting intestinal type and COX-2 
positivity are particularly beneficial, these two variables might be important factors for patients’ 
prognosis and hence useful in future trials for stratification of patients in adjuvant therapy.   
 
A different mechanism of COX-2 influence on survival may be the possible association with the 
degree of differentiation of the tumours. In paper III we assessed COX-2 expression in relation to 
commonly studied clinicopathological variables. We focused on the largest group in our study, PC, 
and did not find any association between COX-2 expression and lymph node status, LNR, R-status, 
tumour diameter, vascular or perineural infiltration. We found however that COX-2 positivity in 
tumours was strongly associated with high degree of tumour differentiation (Grade I and II). Our 
result are in agreement with studies of cultured pancreatic cancer cells, where only moderately and 
highly differentiated pancreatic cancer cell lines expressed COX-2 107;112;167, and with studies on 
human pancreatic adenocarcinoma tissue, where high COX-2 expression was observed  mainly in 
well differentiated lesions145.  As we expected, the joint effects of COX-2 status and differentiation 
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grade on survival showed that the subgroup of patients with COX-2 positive/well differentiated 
tumours had a significantly better survival compared to patients with COX-2 negative/poorly 
differentiated tumours. Thus the presence of COX-2 expression in these tumours appears to be a 
marker of favorable prognosis closely linked to the degree of tumour differentiation.  
In Paper II we showed that LNR independently predicted survival in resected pancreatic cancer. To 
explore this further, we examined also the joint effects of COX-2 status and LNR. The results clearly 
showed that patients with COX-2 negative tumours and unfavorable LNR (LNR >0.2) had the worst 
prognosis (Paper III, Fig. 3b). Finally, multivariate analysis showed that COX-2 negativity of the 
tumours and high LNR (LNR>0.2) independently predicted poor prognosis (Paper III, Table 2). The 
grade of differentiation could not be included in the same analysis as this was strongly correlated to 
COX-2. 
Our results are partly contrary to two large published studies which, found that COX-2 positive 
tumours were associated with reduced survival in patients with pancreatic cancer 102;105. Although the 
patients groups in these studies are larger than in our study, the methodological differences in the 
selection of patients and / or immunohistochemical techniques employed, raise some doubts on the 
results of these studies. In the study of Juuti102, more than 30 years old specimens were included. It is 
well known that for immunohistochemical staining protocol, aging of the fixed tumour tissue might 
interfere with staining process168. Moreover, the variations in fixation protocols over time might also 
result in inadequate staining. In the study of Matsubayashi105, COX-2 staining was performed on 
tissue microarrays. Since COX-2 expression is often heterogeneous104;111;145 in the pancreatic cancer, 
the actual number of COX-2 positive tumours in this study might be underestimated.  
Taken together, the results from Papers II and III demonstrated that both LNR and COX-2 expression 
are independent prognostic factors in pancreatic cancer and might therefore be used for stratification 
of patients for clinical trials with adjuvant treatment.  
 
8.2.3 PGE2 effects in pancreatic cancer stroma  
In Paper IV we studied the involvement of the major product of COX-2, PGE2, in the interaction of 
the pancreatic stellate cells with cancer cells. To examine the cellular mechanism of these 
relationships, we studied cultured pancreatic stellate cells, and explored the effect of PGE2 at a 
cellular level.  
Immunohistochemistry performed on tumour sections from patients with PC, showed COX-2 
expression in the cancer cells and strong staining with α-SMA, an indicator of the presence of 
activated stellate cells, in the tumour stroma. However, we did not find any detectable double staining 
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of COX-2 and α-SMA in the stroma. This was further examined by immunofluorescence, with the 
same outcome. However, in the cultured stellate cells, COX-2 expression was clearly detected, and 
was constant in different passages. 
Co-culture of pancreatic cancer cells with PSC resulted in induction of COX-2 in the stellate cells, 
and showed that this induction apparent to be mediated by interleukin I, secreted from the cancer 
cells. We also found that PGE2, via cAMP, inhibited collagen- and DNA-synthesis in the stellate cells. 
  
Multiple lines of evidence suggest that pancreatic stellate cells (PSC) have an essential role in the 
development of pancreatic cancer desmoplasia 10;70;75;85;146. Studies of human and rat PSC in culture 
have identified a number of growth factors, cytokines, and hormones as regulators of pancreatic 
stellate cell activation 70. However, PGE2 influence on the function of the pancreatic stellate cells, 
particularly the effect on pancreatic fibrosis and cell proliferation, is still uncertain.  
To gain insight into the mechanism of PGE2 effect in pancreatic stellate cells, we first examined 
PGE2 signalling pathways in these cells. PGE2 may affect cells through EP and FP receptors130;131. 
Pancreatic stellate cells express mainly EP2 and EP4 receptors80;81;169 with cAMP as a second 
messenger.   
We therefore examined the effect of PGE2 on cAMP accumulation in the stellate cells and found that 
PGE2 induces strong, dose-dependent accumulation of cAMP (Paper IV, Fig.3). We also found that 
PGE2 induced cAMP accumulation mainly through stimulation of EP2 receptors. Inhibition of the 
EP4 receptor did not show any changes in cAMP accumulation.  
Furthermore, we tested the effect of PGE2 on collagen synthesis. It is known that TGFβ1 stimulates 
collagen synthesis in pancreatic stellate cells70;76;77. In our study, we could not detect any direct effect 
of PGE2 on collagen synthesis. However, we observed that treatment with PGE2 suppressed the 
increase in collagen synthesis stimulated by TGFβ1. As the same effect was observed by the 
treatment with forskolin (a direct activator of adenylyl cyclase), the result suggests that it was a 
cAMP mediated effect. As we could not observe induction of COX-2 in the stellate cells by TGFβ1, 
pretreatment with indomethacin (non-selective COX inhibitor) did not affect TGFβ1-induced 
collagen synthesis. 
We then examined how PGE2 affects stellate cell proliferation. In our experiments, we could not 
detect any direct effect of PGE2 or forskolin on DNA synthesis. However, both PGE2 and forskolin 
significantly inhibited PDGF- stimulated DNA synthesis, suggesting that this effect was mediated by 
cAMP. Pretreatment of the cells with indomethacin did not affect PDGF- stimulated DNA synthesis. 
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Taken together we found that COX-2 is mainly expressed in carcinoma cells, suggesting that the 
cancer cells are the main source of PGE2 in pancreatic tumours. In the pancreatic stellate cells, PGE2 
has both the antiproliferative and antifibrotic effects (Paper IV). Thus, inhibition of COX-2 may 
inadvertently accelerate fibrosis progression in pancreatic cancer. 
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9. Conclusions 
 Addressing the specific aims of our studies, the main conclusions of this thesis are the following:  
 
 1. Histopathological evaluation and exact diagnostic identification of tumour origin in the patients 
operated with pancreatoduodenectomy is challenging. We found that slide review changed the 
diagnosis in 27% of the patients. Distal bile duct cancer was found to be most frequently 
misdiagnosed (53%). Precise predetermined diagnostic criteria, with special focus on the anatomical 
site of origin, are essential to improve the accuracy of diagnosis. Furthermore, high workload per 
pathologist increases the precision of the histopathologic diagnosis.  
 
2. In patients operated with pancreatoduodenectomy, N status and LNR are superior to the number of 
metastatic nodes as prognostics indicators. The predictive value of these variables depends on the 
cancer origin. In ampullary and distal bile duct cancer, N status discriminates between subgroups of 
patients with different long-term survival whereas in pancreatic cancer, LNR is clearly more 
powerful in prognostic subclassification.  In patients with pancreatic cancer, multivariat analysis 
identified LNR > 0.2 as an independent predictor of poor long-term survival. LNR could therefore be 
proposed as a standard, alternative measure of nodal involvement in pancreatic cancer.  
 
3. COX-2 is overexpressed in more than 70% of pancreatic, ampullary and distal bile duct cancers 
and is associated with the histopathological type of differentiation, with the degree of differentiation, 
and with a favourable prognosis. In pancreatic cancer, in a multivariate model, COX-2 negative 
tumours and LNR > 0.2, independently predicted poor prognosis 
 
4. When assessed by immunohistochemistry, COX-2 is mainly expressed in pancreatic carcinoma 
cells, and these cells are regarded as the main source of PGE2 in pancreatic cancer tumour tissue. 
COX-2 was not detected in the stroma, however COX-2 was detected in the cultured pancreatic 
stellate cells (PSC), and could be further induced by interleukin-1β (IL-1β), epidermal growth factor 
(EGF), thrombin, and PGE2, but not by transforming growth factor-β1 (TGFβ). Treatment of PSC 
with PGE2 suppressed both TGFβ-stimulated collagen synthesis and PDGF-stimulated DNA 
synthesis, suggesting that inhibition of COX-2 may inadvertently accelerate fibrosis progression in 
pancreatic cancer. 
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COX-2 overexpression in resected pancreatic head
adenocarcinomas correlates with favourable
prognosis
Ewa Pomianowska1,2*, Aasa R Schjølberg1,3, Ole Petter F Clausen3 and Ivar P Gladhaug1,2
Abstract
Background: Overexpression of cyclooxygenase-2 (COX-2) has been implicated in oncogenesis and progression of
adenocarcinomas of the pancreatic head. The data on the prognostic importance of COX expression in these
tumours is inconsistent and conflicting. We evaluated how COX-2 overexpression affected overall postoperative
survival in pancreatic head adenocarcinomas.
Methods: The study included 230 consecutive pancreatoduodenectomies for pancreatic cancer (PC, n = 92),
ampullary cancer (AC, n = 62) and distal bile duct cancer (DBC, n = 76). COX-2 expression was assessed by
immunohistochemistry. Associations between COX-2 expression and histopathologic variables including degree
of differentiation, histopathologic type of differentiation (pancreatobiliary vs. intestinal) and lymph node ratio
(LNR) were evaluated. Unadjusted and adjusted survival analysis was performed.
Results: COX-2 staining was positive in 71% of PC, 77% in AC and 72% in DBC. Irrespective of tumour origin,
overall patient survival was more favourable in patients with COX-2 positive tumours than COX-2 negative (p = 0.043 in
PC, p = 0.011 in AC, p = 0.06 in DBC). In tumours of pancreatobiliary type of histopathological differentiation, COX-2
expression did not significantly affect overall patient survival. In AC with intestinal differentiation COX-2 expression
significantly predicted favourable survival (p = 0.003). In PC, COX-2 expression was significantly associated
with high degree of differentiation (p = 0.002). COX-2 and LNR independently predicted good prognosis in a
multivariate model.
Conclusions: COX-2 is overexpressed in pancreatic cancer, ampullary cancer and distal bile duct cancer and
confers a survival benefit in all three cancer types. In pancreatic cancer, COX-2 overexpression is significantly
associated with the degree of differentiation and independently predicts a favourable prognosis.
Background
Primary adenocarcinomas located in the pancreatic head
arise from the ampulla, the distal bile duct, or the pancre-
atic ductal structures. Due to the topological proximity of
these structures, resectable adenocarcinomas arising from
any of these three anatomical locations are typically
resected by the same surgical procedure, i.e. curative-
intent pancreatoduodenectomy. The considerable vari-
ation in reported frequencies for the individual tumour
sites suggests that the precise tumour origin may be dif-
ficult to determine [1] and that the applied methods for
histopathological determination of the cancer origin varies
widely among institutions [2]. Adenocarcinomas from all
three locations may be of pancreatobiliary or intestinal
type of differentiation [3].
Overexpression of cyclooxygenase-2 (COX-2) has been
described in several tumours, including colon, stomach,
breast, lung, and urinary bladder [4-16]. The COX-2 ex-
pression is a component of the cellular response to in-
flammation and is induced by several extracellular or
intracellular stimuli, including proinflammatory cyto-
kines, infectious agents, mitogens, hormones and growth
factors [17,18]. Several studies have reported overexpres-
sion of COX-2 in subsets of pancreatic adenocarcinomas
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in 37 – 80% of the tumours investigated [19-26]. In-
creased COX-2 expression has also been demonstrated
in pancreatic intraepithelial neoplasias (PanINs) [27-30].
However there is relatively few data on COX-2 expres-
sion in the two other types of pancreatic head adenocar-
cinomas, ampullary cancer [31-33] and distal bile duct
cancer [34]. Data on prognostic relevance of COX-2
overexpression in all these tumours has been inconsist-
ent and conflicting although most reports indicate an in-
verse relationship between COX-2 overexpression and
survival rates in pancreatic cancer [19,21] and ampullary
cancer [32].
The aim of the present study was to examine the prog-
nostic relevance of COX-2 expression in adenocarcinomas
from the three separate anatomical sites of origin in the
pancreatic head. The data shows that COX-2 is overex-
pressed in all three types of pancreatic head adenocarcin-
omas and that COX-2 overexpression is associated with
better survival. In contrast to previous reports, COX-2
overexpression was found to be an independent prognostic
factor for better survival in pancreatic adenocarcinoma.
Methods
Patients
The study included 230 consecutive patients (103 women
and 127 men) undergoing a standard Whipple’s procedure
for adenocarcinoma with curative intent 1998 -2011 at
Oslo University Hospital, Rikshospitalet. The study was
approved by the Regional Committee for Medical and
Health Research Ethical for Southern Norway.
Standard demographic, clinicopathological, and tumour-
specific data were collected retrospectively from hospital
records. Overall survival data was obtained from the
Norwegian Population Registry, updated June 20, 2013.
Since all Norwegian inhabitants receive a unique personal
identification number, no patients were lost to follow-up
in the present study. Patients were followed until death or
censored after maximum five years (60 months). By the
end of the study 177 patients were dead. Median follow-up
for the remaining 53 patients was 62 months (interquartile
range 29 -119 months). Perioperative death (defined as
death within 30 days of operation) was included in the
analyses (four patients). Analysis excluding perioperative
death gave similar results. None of the patients received
preoperative chemotherapy or chemoradiotherapy. From
2008, adjuvant chemotherapy with 5-fluororuracil was
recommended for eligible patients operated for pancreatic
cancer. Thirty-nine percent of the patients (13 of 33) oper-
ated in this period received adjuvant chemotherapy
(5-FU-based in 11 patients, 2 patients received gemcitabine).
Histopathological evaluation of resection specimens
The resection specimens were examined according to a
standardized protocol as described previously [1,35]. All
registered parameters of the prospectively collected data
base, including anatomic site of tumour origin, where
later reevaluated by slide review [1]. The histological
type of differentiation was evaluated and all tumours
were classified either as intestinal or pancreatobiliary
type [3,36]. In brief, pancreatobiliary tumours typically
have simple or branching glands and small solid nests of
cells surrounded by a desmoplastic stroma, and have
cuboideal to low columnar epithelium arranged in a sin-
gle layer and the nuclei are rounded but with marked
variation in size and shape from one cell to the next. In-
testinal tumours typically resembled colon cancer, have
tall and often pseudostratified columnar epithelium
with oval nuclei located in the more basal aspect of the
cytoplasm, and there may also often be presence of
mucin [36,37].
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was sectioned
(3 μm), dried at 60°C, and processed in a Ventana Bench-
Mark Ultra machine (Ventana Medical Systems Inc. (Tucson
Arizona USA). Slides were incubated with monoclonal
anti-COX-2 antibodies (Thermo Fischer Scientific rabbit),
Universal Alkaline Phosphatase Red Detection Kit (Ultra
View 760-501) and αSMA (Dako M.0851), DAB (Ultra
View 760-500). Additional immunostaining on duplicates
of twenty slides was performed with monoclonal COX-2
mouse antibody Invitrogen (Camarillo, CA, USA). Slides
were counterstained with haematoxylin, fixed, mounted
and analyzed using an inverted light microscope (Olympus,
Center Valley, PA, USA).
Evaluation of COX-2 immunostaining
Immunohistochemistry was performed on whole tumour
slices, which were assessed without prior knowledge of
the clinical and pathological parameters. In each section,
five different representative high-power fields (100×)
with tumour infiltration were selected and examined by
light microscopy. The intensity of staining was estimated
on a scale from 1-3 (1-negative, 2-moderate, 3-strong).
Cells were considered positive only if COX-2 intensity
was moderate or strong. The extent of the immunola-
beling was assessed as the percentage of positively
stained tumour cells and was expressed on the scale
from 1-3 where 1 represented less than 10% cells stained,
2 represented 10-50% and 3 over 50%. Since COX-2 dem-
onstrated considerable heterogeneity within individual
cases, the final immunoscore was obtained as the average
of the numeric scores for five high-power fields of each
case considered positive in intensity scoring. Based on
histograms of the staining for all tumours, the optimal
cut-off value for discrimination between negative and
positive staining was found to be 1.4. Islets of Langer-
hans and mucosa of the duodenum were moderately to
Pomianowska et al. BMC Cancer 2014, 14:458 Page 2 of 10
http://www.biomedcentral.com/1471-2407/14/458
strongly positive for COX-2, including those tumours
with no COX-2 expression, and served as internal con-
trols. Identical sections with omission of the primary
antibody were used as negative controls. To test the val-
idity of the Thermo antibody used for the study cohort,
we performed additional immunostaining with a different
monoclonal COX-2 mouse antibody, Invitrogen (Camarillo,
CA, USA), on duplicates of twenty pancreatic cancer slides
from the study cohort. The results were identical (Figure 1a
and e). As Thermo antibody was not suitable for western
blotting (producer recommendation), only the Invitrogen
antibody was subjected to analysis by western blotting.
The results showed a highly specific bond for COX-2
(Figure 1f).
Almost half of study specimens (44%) were evaluated
independently by two examiners (EP and AS) and kappa
interobserver was 0.73, indicating substantial agreement
(95% CI 0.6-0.9).
Statistical analysis
Associations between variables were examined using
Chi-square test, Fisher’s exact test and Mann-Whitney
test. Continuous variables were reported as median with
corresponding range or interquartile range (IQR). Un-
adjusted survival analysis was performed using the
Kaplan-Meier method, comparing curves using log-rank
test. Multivariable Cox regression analysis was used for
adjusted survival analysis. Possible interactions were eval-
uated by inclusion of an interaction term in the models.
For all tests, a two-sided p < 0.05 was considered statisti-
cally significant. Statistical analyses were performed in
SPSS 19 for Windows (SPSS Inc., Chicago, IL).
Results
The study cohort consisted of 230 patients consecutively
resected for adenocarcinomas originating from the am-
pulla (AC) (n = 62, 27%), distal bile duct (DBC) (n = 76,
33%), or pancreas (PC) (n = 92, 40%). Median age at time
of resection was similar for the three groups (67 years,
range 37-83; p = 0.463 Kruskal-Wallis). Overall 5-year
(actual) survival was 5% for PC, 16% for DBC, and 44%
for AC (p < 0.001).
COX-2 expression and prognosis in ampullary, distal bile
duct and pancreatic cancer
COX-2 staining was very similar in all three tumour
types, with a positivity rate of 71% in PC, 72% in DBC,
and 77% in AC. The COX-2 expression was detected in
the cytoplasm of cancer cells in all three types of adeno-
carcinoma. No COX-2 immunostaining was detected in
the stroma cells (Figure 1a,b, and e). The expression
pattern showed heterogeneity both among different tu-
mours and within the individual tumour, as areas with
moderate to strong staining coexisted with negative
areas within the same tumour (Figure 1c). Islet cells
expressed moderately to strong COX-2 staining in all cases
including those with no COX-2 expression in the tumour
(Figure 1d). Irrespective of tumour origin, overall patient
survival was more favourable in COX-2 positive than
COX-2 negative tumours (Figure 2a-c). This was particu-
larly prominent in AC (p = 0.011) and PC (p = 0.043)
whereas the same tendency was seen in DBC although not
reaching significance (p = 0.06). COX-2 expression varied
according to the type of histological differentiation. In
tumours with pancreatobiliary type of differentiation,
two thirds of the tumours were COX-2 positive irre-
spective of anatomical origin (67%, 69%, and 68% in AC,
DBC and PC, respectively). However there was no sig-
nificant difference in overall survival when comparing
COX-2 positive and negative tumours in this group
(Figure 2d-f ). All PC and DBC tumours with intestinal
type of differentiation were COX-2 positive whereas
84% of the intestinal AC tumours expressed COX-2.
The survival data of the intestinal AC tumours showed
a favourable prognosis for patients with tumours express-
ing COX-2 (p = 0.003) (Figure 2g-i).
Factors associated with prognosis in pancreatic
adenocarcinoma
COX-2 expression status was compared across clinical
parameters associated with survival in the subgroup
consisting of the 92 patients resected for pancreatic
adenocarcinoma. The median survival for patients with
COX-2 positive tumours was 18 months (95% CI 14-22)
as compared to 11 months (95% CI 9.6-12) for patients
with COX-2 negative tumours (p = 0.043). COX-2 positive
tumours were more likely associated with high degree of
differentiation (p = 0.002) and with intestinal type of dif-
ferentiation, although, the latter did not reach significance
(p = 0.099) (Table 1) probably due to the low number of
tumours of the intestinal differentiation type.
There was no association with COX-2 positivity and
R-status, lymph node ratio (LNR), lymph node status,
tumour diameter, T classification, and vascular or peri-
neural infiltration (Table 1). Since tumours expressing
COX-2 were significantly more likely to be highly differ-
entiated than COX-2 negative tumours, the joint effects
of COX-2 status and differentiation grade on survival
were assessed by Kaplan-Meier analysis, stratifying for
COX-2 status (positive vs. negative) and differentiation
grade (grade 1 and 2 vs. grade 3 and 4) (Figure 3a).
Patients whose tumours did not express COX-2 and
had a low differentiation grade (grade 3 and 4) had sig-
nificantly poorer survival than the other three groups
(p = 0.006).
In a previous report we found that LNR independently
predicted prognosis in a multivariate model for survival
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in resected pancreatic cancer [38]. We thus also examined
the joint effects of COX-2 status and LNR, and found that
patients with COX-2 negative tumours and LNR >0.2 had
significantly worst prognosis (p < 0.001) (Figure 3b).
In a multivariate analysis model including COX-2
expression, LNR, tumour size, margin status, vascular
and perineural infiltration, COX-2 negative tumours
and LNR > 0.2 independently predicted poor prognosis
Figure 1 COX-2 expression in tumour tissue from pancreatic cancer. a-d Double immunostaing with monoclonal anti-COX-2 antibody
(Thermo Fischer Scientific rabbit) and monoclonal anti-αSMA (Dako). COX-2 tumour positive cells (red colour), αSMA positive stromal cells (brown
colour). a magnification × 100, b magnification × 200, c Heterogeneity in COX-2 expression within pancreatic cancer tissue. Areas with moderate
to strong staining (thick arrow) coexist with COX-2 negative areas (thin arrow), (magnification x 100) d Moderately to strong COX-2 staining in islet cells
(thin arrow), pancreatic cancer negative for COX-2 staining, (magnification x 100). e Immunohistochemistry of COX-2 expression in tumour tissue from
pancreatic cancer. Immunostaining with monoclonal COX-2 mouse antibody Invitrogen (the same tumour as in a), magnification x 100. f Western blot
of COX-2 expression in the moderately differentiated pancreatic cancer cell lines BxPC3 and HPAFII known to overexpress COX-2, with and without
induction by interleukin 1 (Il-1), showed a specific bond for COX-2 (70 kDA) (monoclonal COX-2 mouse antibody Invitrogen).
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Figure 2 Overall survival analysis stratified by COX-2 expression. a Ampullary cancer (AC), b Distal bile duct cancer (DBC), c Pancreatic
cancer (PC). d-f Overall survival analysis for AC, DBC and PC with pancreatobiliary differentiation stratified by COX-2 expression. g-i Overall survival
analysis for AC, DBC and PC with intestinal differentiation stratified by COX-2 expression.
Pomianowska et al. BMC Cancer 2014, 14:458 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/458
(Table 2). Since there was a strong correlation between
COX-2 expression and differentiation grade (p = 0.002)
it was not possible to include differentiation grade in
the same model.
Only a minority of the patients received adjuvant
chemotherapy. Although the numbers are small, there
was no difference in survival between patients with
COX-2 positive and COX-2 negative tumours who re-
ceived adjuvant treatment.
Discussion
There is a large body of epidemiological, clinical and
molecular evidence suggesting that COX-2 is implicated
in the oncogenesis and progression of gastrointestinal
malignancies, including adenocarcinomas derived from
pancreatic head structures. It has previously been shown
that COX-2 is upregulated in subsets of pancreatic, am-
pullary and distal bile duct adenocarcinomas although
the proportion of upregulated tumours varies in the
Table 1 Clinicopathological variables in 92 consecutive pancreatoduodenectomies for pancreatic cancer stratified by
COX-2 status
Characteristic n(%) COX2-neg. n(%) COX2-pos. n(%) pa
COX-2
Positive 65 (71%)
Negative 27 (29%)
Tumour size
≤ 20 mm 15 (16%) 3 (20%) 12 (80%)
> 20 mm 77 (84%) 24 (31%) 53 (69%) 0.54b
Lymph node metastasis
N0, n (%) 25 (27%) 5 (20%) 20 (80%)
N1, n (%) 67 (73%) 22 (33%) 45 (67%) 0.229
Lymph node ratio (LNR)c
≤ 0.2 54 (59%) 13 (24%) 41 (76%)
> 0.2 37 (41%) 13 (36%) 24 (65%) 0.251
Vascular invasion
No, n (%) 30 (33%) 12 (40%) 18(60%)
Yes, n (%) 62 (67%) 15 (24%) 47 (76%) 0.119
Perineural infiltration
No, n (%) 15 (16%) 3 (20%) 12 (80%)
Yes, n (%) 77 (84%) 24 (31%) 53 (69%) 0.54b
T classification
T1 3 (3%) 1 (33%) 2 (67%)
T2 6 (7%) 1 (17%) 5 (83%)
T3 83 (90%) 25 (30%) 58 (70%) 0.851b
R1 resection status, n (%)
R0, n (%) 40 (44%) 10 (25%) 30 (75%)
R1, n (%) 52 (56%) 17 (33%) 35 (67%) 0.422
Degree of differentiation
Grade I, II 53 (58%) 9 (17%) 44 (83%)
Grade III, IV 39 (42%) 18 (46%) 21 (54%) 0.002
Type of differentiation
Pancreaticobiliary, n (%) 84 (91%) 27 (32%) 57 (68%)
Intestinal, n (%) 8 (9%) 0 (0%) 8 (100%) 0.099b
PC, pancreatic adenocarcinoma.
aChi-square test, when not otherwise specified.
bFisher’s Exact Test.
cLNR assessment of 91 patients since in one specimen no lymph nodes were retrieved.
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different reports. Furthermore, data on the prognostic
importance of COX-2 expression in these tumours is
conflicting. In pancreatic adenocarcinoma, two studies
reported that COX-2 expressing tumours were associ-
ated with worse overall prognosis [19,21] whereas other
studies have suggested a trend towards better prognosis
for tumours with high COX-2 expression [22] or no as-
sociation at all [39-41]. The present data on pancreatic,
distal bile duct and ampullary adenocarcinomas indi-
cates a more favourable overall survival for patients with
COX-2 expressing tumours.
In periampullary and pancreatic head tumours, we
have previously shown that histologic subtyping of these
tumours into intestinal and pancreatobiliary types corre-
lates with cell-type specific markers [36] and prognosis
[3,37]. As COX-2 is thought to be expressed in epithelial
cells throughout the gastrointestinal tract [5,12,42] it
was of particular interest to examine whether there are
differences in COX-2 expression in the intestinal and
pancreatobiliary subtypes. Of note, most intestinal ampul-
lary tumours (84%) were COX-2 positive, and in particu-
lar, all intestinal pancreatic and distal bile duct tumours
were COX-2 positive. Patients with ampullary cancers of
the intestinal subtype, which expressed COX-2, had a
favourable prognosis with a 5-year actual survival of 60%.
Histopathologic type of differentiation combined with bio-
markers or gene expression profiles has recently attracted
interest as important factors for outcome as well as strati-
fication for adjuvant chemotherapy in ampullary adeno-
carcinoma [43,44].
The finding in the present study that COX-2 expres-
sion correlates with a favourable prognosis in pancreatic
cancer can be explained by the fact that there is a statis-
tically significant association between COX-2 positivity
and high degree of differentiation. More than 80% of tu-
mours with high differentiation grade showed overexpres-
sion of COX-2. This result is consistent with previous
observations from studies of cultured pancreatic cancer
cells and pancreatic cancer tissue. In cultured tumour cells
COX-2 expression was found to be restricted to moder-
ately and highly differentiated pancreatic cancer cell lines
[23,26,45]. In human pancreatic adenocarcinoma tissue,
well differentiated lesions expressed COX-2 to the highest
degree, whereas there was less expression of COX-2 in
moderately and poorly differentiated lesions [30]. In our
study, the subgroup of patients with COX-2 positive/well
differentiated tumours had a significantly better survival
compared to patients with COX-2 negative/poorly differ-
entiated tumours, whereas COX-2 positive/poor differen-
tiation and COX-2 negative/high differentiation formed
a b
Figure 3 Overall survival analysis for patients with pancreatic cancer stratified by COX-2 expression and a degree of differentiation,
b Lymph node ratio (LNR).
Table 2 Multivariate Cox regression analysis of
histopathologic factors in 92 patients with pancreatic
cancer
p-value HR 95% CI
R-status (R1vs R0) 0.87 1.038 0.65 - 1.65
Vascular invasion
(Involved vs non- involved)
0.455 1.208 0.74 - 1.98
Perineural infiltration
(Involved vs non- involved)
0.359 1.369 0.70 - 2.68
Tumour size
(> 20 mm vs ≤ 20 mm)
0.315 1.434 0.71 - 2.90
COX-2 expression
(Negative vs Positive)
0.047 1.642 1.01 - 2.68
Lymph node ratio
(LNR) (> 0.2 vs ≤ 0. 2)
0.032 1.757 1.05 - 2.94
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an intermediate group with respect to survival. Thus the
presence of COX-2 expression in these tumours appears
to be a marker of favourable prognosis closely linked to
the degree of tumour differentiation. Consistent with the
latter the strong statistical association between COX-2
expression and differentiation grade precluded inclusion
of both variables in the same multivariable model for
survival.
The precise function of COX-2 in pancreatic cancer
development is not known. In the normal pancreas, only
islet cells always express COX-2 [24]. In transgenic mice
models, overexpression of COX-2 in normal pancreatic
ductal cells results in development of dysplastic changes
resembling IPMNs and PanINs [46,47] suggesting a pri-
mary role of pancreatic cell COX-2 overexpression in
the initiation of ductal adenocarcinoma. Recent evidence
suggests that this is an intrinsic role of pancreatic cells
independent of prostaglandins from the tumour micro-
environment [48]. These observations support the con-
cept that COX-2 overexpression might be a causal factor
in pancreatic cancer development. It has also been sug-
gested that pancreatic cancers that lack COX-2 (and
COX-1) depends on exogenic prostaglandins from stromal
fibroblasts for proliferation and other cancer-promoting
effects [49]. Since COX-2 overexpression is implicated in
tumour development, its expression in pancreatic cancer
was hypothesized to result in a poor patient prognosis
[19]. This hypothesis is difficult to reconcile with the ob-
servation that in fully developed tumours, COX-2 expres-
sion has been shown to be a function of differentiation
status, with highest expression in well differentiated
tumours [30]. In addition, it has been demonstrated
that COX-2 expression varies markedly throughout the
pathological process of pancreatic neoplasia. COX-2
expression increases in a stepwise manner with each
initial stage of neoplastic progression up to the PanIN
2 stage, whereas COX-2 expression was relatively lower in
invasive cancers [30].
Some of the discrepancies in results between our study
and the studies by Juuti et al [19] and Matsubayashi et al
[21] might be explained by methodological differences in
patient sampling and/or tumour immunohistochemistry
techniques. Since it is well known that it can be difficult
to determine the precise anatomical origin of tumours of
the pancreatic head, all cancers in the present series
were re-evaluated for correct sub-classification into am-
pullary, distal bile duct or pancreatic tumours. There are
also certain differences pertaining to the immunohisto-
chemistry protocols that differ in our study compared to
the studies by Juuti et al [19] and Matsubayashi et al
[21]. In the work of Juuti, more than 30 years old speci-
mens were included in the study cohort. It is known that
for immunohistochemical staining protocols aging of
fixed tumour tissue might interfere with staining [50].
Not only aging of the waxed specimen itself, but also
variations in fixation protocols over time may result in
inadequate staining. This may partly explain the low fre-
quency of COX-2 staining (36%) in their data, compared
to 55-80% in most other reports [20,22,23,25,26,41,51].
Since COX-2 expression in pancreatic tumours often is
heterogeneous [24,29,30], the actual number of COX-2
positive tumours might be underestimated unless immu-
nohistochemistry is performed on whole slide sections
and assessed on multiple different high-power fields within
each tumour. In the study of Matsubayashi [21], assessment
of COX-2 staining was performed on tissue microarrays.
Although this method has many advantages, tissue micro-
arrays might not be the optimal method for assessment
of COX-2 staining even if two cores of tumour tissues
were studied from each tumour. This may partly ex-
plain the lower proportion of tumours expressing
COX-2 in some studies [19,21] and hence the differ-
ences in patient survival.
Conclusion
COX-2 is overexpressed in pancreatic cancer, ampullary
cancer and distal bile duct cancer and confers a survival
benefit in all three cancer types. The overexpression is
consistently linked to the histopathological type of differ-
entiation and to the degree of differentiation. In pancreatic
adenocarcinoma, COX-2 overexpression independently
predicts a favourable prognosis.
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Inhibitory effects of prostaglandin E2 on collagen
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Abstract
Background: Several studies have described an increased cyclooxygenase-2 (COX-2) expression in pancreatic
cancer, but the role of COX-2 in tumour development and progression is not clear. The aim of the present study
was to examine expression of COX-2 in cancer cells and stromal cells in pancreatic cancer specimens, and to
explore the role of PGE2 in pancreatic stellate cell proliferation and collagen synthesis.
Methods: Immunohistochemistry and immunofluorescence was performed on slides from whole sections of tissue
blocks using antibodies against COX-2 and α-smooth muscle actin (αSMA). Pancreatic stellate cells (PSC) were isolated
from surgically resected tumour tissue by the outgrowth method. Cells were used between passages 4 and 8.
Collagen synthesis was determined by [3H]-proline incorporation, or by enzyme immunoassay measurement of
collagen C-peptide. DNA synthesis was measured by incorporation of [3H]-thymidine in DNA. Cyclic AMP (cAMP)
was determined by radioimmunoassay. Collagen 1A1 mRNA was determined by RT-qPCR.
Results: Immunohistochemistry staining showed COX-2 in pancreatic carcinoma cells, but not in stromal cells.
All tumours showed positive staining for αSMA in the fibrotic stroma. Cultured PSC expressed COX-2, which
could be further induced by interleukin-1β (IL-1β), epidermal growth factor (EGF), thrombin, and PGE2, but not
by transforming growth factor-β1 (TGFβ). Indirect coculture with the adenocarcinoma cell line BxPC-3, but not
HPAFII or Panc-1, induced COX-2 expression in PSC. Treatment of PSC with PGE2 strongly stimulated cAMP accumulation,
mediated by EP2 receptors, and also stimulated phosphorylation of extracellular signal-regulated kinase (ERK).
Treatment of PSC with PGE2 or forskolin suppressed both TGFβ-stimulated collagen synthesis and PDGF-stimulated
DNA synthesis.
Conclusions: The present results show that COX-2 is mainly produced in carcinoma cells and suggest that the
cancer cells are the main source of PGE2 in pancreatic tumours. PGE2 exerts a suppressive effect on proliferation
and fibrogenesis in pancreatic stellate cells. These effects of PGE2 are mediated by the cAMP pathway and suggest
a role of EP2 receptors.
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Background
Pancreatic adenocarcinoma is one of the most lethal
cancers of all solid malignancies with a 5 year survival
of less than 5% [1-3]. A particular feature of primary
pancreatic adenocarcinoma is the extensive fibrotic
stromal reaction known as tumour desmoplasia surround-
ing these tumours [4-6]. There is increasing evidence that
stromal cells are of major importance for tumour progres-
sion, by interacting in many ways with the malignant cells,
such as reciprocal paracrine proliferative stimulation and
angiogenesis, contributing to the early invasive growth
and metastasis of this tumour [6]. These observations
have raised the possibility that targeting the stromal cells
to interrupt paracrine stromal signalling mechanisms may
represent a new treatment strategy in pancreatic cancer.
Animal studies have also indicated that targeting the
tumour stroma of pancreatic cancer may improve drug
delivery [7-9].
Multiple lines of evidence suggest that pancreatic
stellate cells (PSC) have a major role in the development
of pancreatic cancer desmoplasia [4-6,10]. These cells,
which are normally quiescent cells in the pancreas, are
induced during pancreatic injury to undergo transform-
ation into a myofibroblast-like phenotype expressing alpha
smooth muscle actin (αSMA). Studies of human and rat
PSC in culture have identified a number of growth factors,
cytokines, and hormones as regulators of pancreatic
stellate cell activation [6]. Activation promotes PSC
proliferation, migration, and extracellular matrix (ECM)
deposition.
Overexpression of COX-2 has been reported in a
number of epithelial cancers, including pancreatic can-
cer [11-16]. Transgenic mouse models have suggested
that COX-2 overexpression in pancreatic ductal cells
contributes to pancreatic tumour development [17,18].
Upregulation of COX-2 leads to increased production
of prostaglandins, in particular PGE2. PGE2 may affect
both cancer cells and different stromal cells through its
effects on EP and FP receptors [19,20]. While EP2 and
EP4 receptors are Gs-coupled receptors that stimulate
adenylyl cyclase activity, EP3 receptors are Gi-coupled and
inhibit adenylyl cyclase activity. EP1 receptors elevate the
intracellular Ca2+-levels through mechanisms that may in-
volve both phospholipase C-dependent and independent
mechanisms [19-21], and FP receptors are Gq-coupled
and elevate intracellular Ca2+-levels [19,20]. In addition,
several of these receptors may signal via G protein-
independent mechanisms [22].
Fibroblasts may be stimulated by PGE2. Elevation of
the intracellular level of cAMP in response to PGE2 or
other stimuli in fibroblasts from different tissues has
been found to limit their proliferation, migration, and
collagen secretion, as well as the differentiation of fibro-
blasts to myofibroblasts [23-25]. These effects appear to
be mediated via EP2 and EP4 receptors. It has also been
reported that PGE2 may promote fibroblast proliferation
through activation of EP1, EP3, or FP signalling [26-29].
In hepatic stellate cells, PGE2 has been found to inhibit
transforming growth factor β (TGFβ)-mediated induction
of collagen mRNA [30], as well as proliferation induced
by platelet-derived growth factor (PDGF) or thrombin
[31,32]. However, the role of PGE2 in pancreatic fibrosis
is not well known. The aim of the present study was to
examine further the effects of PGE2 on pancreatic stellate
cell proliferation and collagen synthesis.
Methods
Patients
The study protocol and patient consent documents were
approved by the Regional Committee for Medical and
Health Research Ethics (REC South East, project num-
ber S-05081), and was in compliance with the Helsinki
Declaration. Written informed consent was obtained from
all study participants. The study included only adults.
Chemicals
Dulbecco’s Modified Eagle’s Medium, Ham’s F12 medium,
RPMI 1640 medium, glutamine, and Pen-Strep (10.000
U/ml) were obtained from Lonza (Verviers, Belgium).
HEPES, amphotericin, and heat-inactivated fetal bovine
serum (FBS) was purchased from Gibco (Grand Island,
NY, USA). Epidermal growth factor (EGF), adenosine 3’:5’-
cyclic monophosphate (cAMP), 3-isobutyl 1-methylxan-
thine (IBMX), L-ascorbic acid, and 3-aminopropionitrile
fumarate salt were obtained from Sigma-Aldrich (St.Louis,
MO, USA). Human platelet derived growth factor (PDGF),
recombinant human transforming growth factor-β (TGF-β),
and recombinant human interleukin-1β (IL-1β) were
obtained from R&D Systems Europe, Ltd (Abingdon,
England). Recombinant interleukin-1 receptor antagonist
(Anakinra®) was a gift from Swedish Orphan Biovitrum
AS, [6-3H] thymidine (20–30 Ci/mmol), [2,8-3H] adeno-
sine 3’,5’-cyclic phosphate ammonium salt (33.0 Ci/mmol),
and L-[2,3-3H] proline (55.0 Ci/mmol) were purchased
from PerkinElmer (Boston, MA, USA). L161982 (N-
[[4’-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)
phenyl]-4 H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]
sulfonyl]-3-methyl-2-thiophenecarboxamide, AH6809 (6-
isopropoxy-9-oxoxanthene-2carboxylic acid), and prosta-
glandin E2 (PGE2) were obtained from Cayman Chemical
(Ann Arbor, MI, USA). Procollagen Type I C-peptide
enzyme immunoassay kit was purchased from Takara
Bio Inc., Japan. All other chemicals were of analytical
quality. Antibodies against phosphorylated AktSer473,
total Akt, dually phosphorylated ERKThr202/Tyr204, and
GAPDH were obtained from Cell Signaling Technology
(Boston, MA, USA). Antibodies against COX-2 were
obtained from Cayman Chemical (Ann Arbor, MI, USA)
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or from Thermo Fischer Scientific Inc (Fremont, CA,
USA). Anti-ERK antibody was from Upstate/Millipore
(Billerica, MA, USA). Antibodies against TGF-β receptor II
and PDGF receptor β were purchased from Cell Signaling
Technology (Boston, MA, USA). Antibody against EP2 re-
ceptor was obtained from Cayman Chemical (Ann Arbor,
MI, USA). Secondary antibodies were purchased from
Bio-Rad Laboratories (Hercules, CA, USA). Antibodies
against vimentin and cytokeratins 7 and 19 were provided
by DAKO (Glostrup, Denmark).
Isolation and culture of human pancreatic stellate cells
Human pancreatic stellate cells (PSC) were isolated by
the outgrowth method developed by Bachem et al. [33].
Pancreatic tissue blocks (100–150 mg) were obtained
during pancreatic surgery from patients with resectable
pancreatic head adenocarcinoma. Altogether, stellate cell
cultures were established from a total of 20 different pa-
tients. Briefly, the tissue blocks were cut using a razor
blade (0.5–1 mm3) and seeded in 10 cm2 uncoated culture
wells (6 per plate; 3–5 pieces per well) in a 1:1 (vol/vol)
mixture of Dulbecco’s modified Eagle medium (DMEM)
with Ham’s F12 medium, supplemented with l-glutamine
(2 mmol/L), 100 U/ml Pen-Strep, 2.5 μg/ml amphotericin,
and 10% FBS. Tissue blocks were cultured at 37°C in a 5%
CO2/air humidified atmosphere. Twenty-four hours after
seeding, the small tissue blocks were transferred to new
culture plates. Culture medium was changed every third
day. The PSCs grew out from the tissue blocks 7 to 10 days
later. The small tissue blocks were removed after 2–3
weeks. After reaching confluence, monolayers were
trypsinized and passaged 1:3. The purity of the cells was
assessed by morphology (most cells were stellate-like,
with long cytoplasmatic extensions; some were also spindle
shaped) and cytofilament staining of αSMA and vimentin.
None of the cells were positive for cytokeratins 7 or 19
(data not shown). All experiments were performed using
cell populations between passage 4 and 8.
Pancreatic adenocarcinoma cell lines
BxPC-3, HPAFII, and Panc-1 pancreatic adenocarcinoma
cell lines were purchased from ATCC (Manassas, VA,
USA). BxPC-3 cells were cultured in RPMI medium
containing 4.5 g/l glucose, HPAFII cells were cultured
in Dulbecco’s modified Eagle’s medium containing 1 g/l
glucose, and Panc-1 cells were cultured in Dulbecco’s
modified Eagle’s medium containing 4.5 g/l glucose.
The media were supplemented with glutamine (2 mM,
or 4 mM in the case of Panc-1), 100 U/ml Pen-Strep,
and 10% fetal bovine serum (FBS). Cells were plated in
Transwell® inserts (Corning Incorporated, Corning, NY,
USA) at a density of 100.000/cm2 in serum-containing
medium and cultured overnight. The next day, medium
was replaced with fresh, serum-free medium, and cells
were cultured overnight. The following day, the Transwells
were transferred to 12 well Costar plates containing stellate
cells in the lower compartment, and cells were cocultured
for 48 hours.
Coculture of pancreatic stellate cells with pancreatic
adenocarcinoma cell lines
Pancreatic stellate cells were plated at a density of
10.000 cells/cm2 in 12 well Costar plates with serum-
containing medium and cultured overnight. The following
day, medium was replaced with fresh, serum-free medium,
and cells were cultured overnight. The next day, the
serum-free medium was changed, and Transwells contain-
ing pancreatic adenocarcinoma cell lines were placed on
top. Cells were cocultured for 48 hours before harvesting
for immunoblotting.
Measurement of DNA synthesis
Pancreatic stellate cells were seeded into 12 well Costar
plates at a density of 10.000 cells/cm2 in serum-containing
medium and cultured overnight. On the following day,
medium was replaced with fresh, serum-free medium.
The next day, the serum-free medium was changed 30 mi-
nutes before addition of agonists. The cells were harvested
after pulsing for 6 hours with [3H]thymidine (18–24 hours
after addition of agonists), and DNA synthesis was mea-
sured as the amount of radioactivity incorporated into
DNA as previously described [34]. Briefly, medium was re-
moved, and cells were washed twice with 0.9% NaCl. The
cellular material was dissolved with 1 ml 0.5 N NaOH for
3 hours at 37°C, collected, mixed with 1 ml H2O, and
precipitated with 0.5 ml 50% trichloroacetic acid (TCA).
The acid-precipitable material was transferred to glass
fiber filters (GF/C Whatman, GE Healthcare, UK) and
washed twice with 5.0 ml 5% TCA, followed by liquid
scintillation counting of the filters in a Packard Tri-Carb
1900 TR liquid scintillation counter.
Measurement of collagen synthesis
Collagen synthesis was assessed by quantification of [3H]
proline incorporation into acetic acid-soluble proteins as
described by Jaster et al. [35]. Pancreatic stellate cells
were plated in 24 well Costar plates at a density of
10.000 cells/cm2 in serum-containing medium and cul-
tured overnight. The following day, medium was replaced
with fresh, serum-free medium. The next day, serum-free
medium was changed, and agonists and/or antagonist
were added. After 24 hours, the medium was replaced
with fresh serum-free medium containing 100 μg/ml as-
corbic acid, 100 μg/ml 3-aminopropionitrile, and 2 μCi/ml
[3H] proline, and fresh agonists were added. The reaction
was stopped 24 hours later, by addition of 50 μl/ml 10 N
acetic acid. After an overnight incubation at 4°C, culture
supernatants were transferred to microcentrifuge tubes,
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mixed with 100 μl/ml FBS, 5 μg/ml rat tail collagen and
250 μl/ml 25% NaCl dissolved in 0.5 N acetic acid, and
incubated at 4°C for 30 minutes. Protein precipitates col-
lected by centrifugation (30 min, 10,000 g) were washed
twice with 5% NaCl, followed by dissolution of the pellet
in 0.5 N acetic acid. [3H] proline incorporation was de-
termined by liquid scintillation counting in a Packard
Tri-Carb 1900 TR scintillation counter. In initial experi-
ments, collagen synthesis was determined in parallell sam-
ples by measurement of procollagen type I C-peptide by
an enzyme immunoassay. The two methods yielded simi-
lar results (data not shown).
RNA extraction and real-time quantitative RT-qPCR
Pancreatic stellate cells were plated at a density of
10.000/cm2 in 20 cm2 wells in serum-containing medium
and cultured overnight. On the following day, medium
was replaced with serum-free medium. The next day the
medium was changed 30 minutes before agonists and/or
antagonist were added, as indicated. The cells were stimu-
lated for 24 hours. Total RNA was prepared from the
samples using RNA Easy Mini kit (Qiagen Inc, Valencia,
CA, USA) and cDNA was synthesized with SuperScript
III Reverse Transcriptase First-Strand cDNA Synthesis kit
according to the manufacturer’s protocol (InVitrogen,
Carlsbad, CA, USA). Quantitative PCR was performed
with Platinum SYBR Green Master Mix (Life Technologies,
Oslo, Norway) on 7900 Real-Time PCR system with 7900
System SDS 2.3 Software (Applied Biosystems) according
to the manufacturer’s protocol. Specific primers for colla-
gen 1A1 were: forward, 5’-TGACGTGATCTGTGACG
AGAC-3’ and reverse, 5’- GGTTTCTTGGTCGGTGG
GT −3’ (Life Technologies Oslo, Norway). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was utilized as
housekeeping gene, and specific primers were: forward,
5’-CCACCATGGAGAAGGCTGGGGCTC-3’ and reverse
5’-AGTGATGGCATGGACTGTGGTCAT3’ (Life Tech-
nologies, Oslo, Norway). The primers were designed using
Primer-BLAST [36]. All reactions were performed in trip-
licates including non-template controls. The results were
analyzed using the ΔΔCt method [37]. Results for collagen
1A1 were normalized to GAPDH, and controls were
assigned a value of 100%.
Cyclic AMP measurement
Pancreatic stellate cells were plated in 12 well Costar wells
at a density of 10.000 cells/cm2 in serum-containing
medium. On the following day, medium was replaced
with fresh, serum-free medium. The next day, medium
was replaced with Krebs-Ringer-Hepes buffer, pH 7.4,
containing 10 mM glucose. After preincubation for
30 minutes, cells were stimulated with PGE2 or forskolin as
indicated in the figure legends. The reaction was stopped
by removing the buffer and adding 5% TCA. cAMP in the
neutralized TCA extract was determined by radioimmuno-
assay as previously described [38].
Immunoblotting
Aliquots with approximately 7000 cells (total cell lysate
prepared in Laemmli buffer) were electrophoresed on
12% (w/v) polyacrylamide gels (acrylamide: N’N’-bis-
methylene acrylamide 30:1). This was followed by protein
electrotransfer to nitrocellulose membranes and immuno-
blotting with antibodies against phospho-Akt, total Akt,
phospho ERK1/2, total ERK, COX-2, and GAPDH, respect-
ively. Immunoreactive bands were visualized with enhanced
chemiluminescence using LumiGLO (KPL Protein research
Products, Gaithersburg, MD, USA).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues from pancrea-
tectomy specimens were sectioned (3 μm), and dried at
60°C. Further processing was carried out in the Ventana
BenchMark Ultra machine (Ventana Medical Systems Inc.
(Tucson Arizona USA) according to the manufacturer’s
recommendations. Slides were incubated with monoclonal
anti-COX-2 antibodies (Thermo Fischer Scientific rabbit),
Universal Alkaline Phosphatase Red Detection Kit (Ultra
View 760–501) and a-SMA (Dako M.0851, DAB (Ultra
View 760–500). Finally, slides were counterstained with
haematoxylin, fixed, mounted and analyzed using an
inverted light microscope (Olympus, Center Valley, PA,
USA).
Immunofluorescence staining
Immunofluorescence staining was performed to examine
COX-2 expression in the tumour slides. Formalin-fixed,
paraffin-embedded tissues from pancreatectomy specimens
were sectioned (3 μm), dried at 60°C and hydrated. Slides
were incubated with monoclonal anti-COX-2 antibody
(Thermo sp21 rabbit) and anti-αSMA (DAKO 1A4 mouse)
for 30 min at room temperature in Ventana diluents. After
washing with PBS, slides were incubated with secondary
antibody conjugates (Alexa 555 anti-rabbit and Alexa 488
anti - mouse) in the dark for 1 hour in Dako diluents.
After three washes with PBS, slides were mounted in
VECTASHIELD containing DAPI (Vector Laboratories
Inc., Burlingame, CA, USA). Fixed cells were observed
under a fluorescence microscope.
Immunofluorescence staining was also performed on
the cultured pancreatic stellate cells. Cells were first
seeded into a Lab-Tek®II Chamber Slide™ System (Nunc
International, Naperville, IL, USA) and were cultured for
24 hours before they were fixed in 4% paraformaldehyde at
room temperature for 15 minutes. Cells were then washed
three times and incubated with 5% BSA for 30 minutes to
block non-specific binding. Slides were further processed
as describe for tumour tissue.
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Statistical analyses
Results are presented as mean ± standard error of the
mean (S.E.M). DNA and collagen synthesis data were ana-
lyzed by one-way ANOVA, and post test using Bonferroni
correction to compare groups, using GraphPad Prism
(version 5.01, GraphPad Software, San Diego, CA, USA).
Results
COX-2 expression in pancreatic cancer cells
COX-2 expression in tumour tissue from pancreatic cancer
was examined by double staining immunohistochemistry
for COX-2 and αSMA. The cancer cells generally exhibited
strong COX-2 staining (Figure 1A). We also found strong
αSMA staining in the tumour stroma, indicating the pres-
ence of activated PSC. However, we could not detect
double staining with COX-2 and αSMA in the stroma
(Figure 1A). This was examined further by immunofluor-
escence, which failed to detect any COX-2 staining in the
stroma (Figure 1B).
COX-2 expression in cultured human PSC
During culture of PSC, immunofluorescence staining in
different passages revealed perinuclear staining with
the COX-2 antibody in cells that were αSMA positive
(Figure 1C). The expression of COX-2, αSMA, EP2 recep-
tors, TGFβ receptors and PDGF receptors was found to
be stable as a function of cell passage number as assessed
by Western blotting (Figure 1D, 1E). Treatment of PSC
with EGF and PGE2 increased the expression of COX-2,
whereas treatment with TGFβ did not. This expression
pattern was observed in cells of both low and high passage
numbers (Figure 1F). PDGF had no significant effect.
Thrombin also induced COX-2 expression (data not
shown). Interleukin-1β (IL-1β) was found to be a potent
inducer of COX-2 expression, with maximal induction ob-
tained at 0.1 ng/ml (Figure 1G). Coculture of pancreatic
adenocarcinoma cell lines with pancreatic stellate cells
was previously found to upregulate COX-2 mRNA in both
stellate cells and adenocarcinoma cell lines [39]. We ex-
amined the effect of coculture of stellate cells with the
adenocarcinoma cell lines BxPC-3, Panc-1, and HPAFII.
Of these, only BxPC-3 cells induced COX-2 protein in the
stellate cells (Figure 2A). Furthermore, this effect was
abolished when the stellate cells were pretreated for one
hour with an IL-1 receptor antagonist (Figure 2B).
PGE2 stimulates EP2-mediated cAMP accumulation in PSC
PGE2 may affect cells through both EP and FP receptors.
Because fibroblasts from different tissues have been found
to express mainly EP2 and EP4 receptors [24,40,41], we
examined the effect of PGE2 on cAMP accumulation in
the stellate cells. When stellate cells were stimulated for
5 min with 100 μM PGE2 or 50 μM forskolin, a direct acti-
vator of adenylyl cyclase [42], in the presence of the
phosphodiesterase inhibitor isobutylmethylxanthine (IBMX),
cAMP levels were elevated 16.8 ± 5.8-fold (mean ± S.E.M.)
above basal levels with PGE2, and 33.0 ± 11.7-fold above
basal with forskolin (n = 7). PGE2 induced a strong, dose-
dependent accumulation of cAMP, both in the absence
and presence of IBMX (Figure 3A). When cells were pre-
incubated with the EP4 receptor antagonist L-161982
[43], no significant inhibition of PGE2-stimulated cAMP
accumulation was observed. In contrast, AH6809, which
is commonly used as en EP2 receptors antagonist [19], al-
most abolished the cAMP response, suggesting that cAMP
accumulation in these cells is mediated mainly by EP2
receptors (Figure 3B).
PGE2 inhibits DNA synthesis in PSC
We next examined how PGE2 affected stellate cells prolifer-
ation. In agreement with previous studies [6,44,45], PDGF
strongly stimulated DNA synthesis (Figure 4A). Epidermal
growth factor (EGF) also stimulated DNA synthesis, al-
though to a lesser extent than PDGF, whereas TGFβ had
non-significant effect. (Figure 4A). In agreement with
these findings, PDGF and EGF, but not TGFβ, significantly
stimulated phosphorylation of both ERK and Akt in the
stellate cells (Figure 4C). Interestingly, PGE2, the FP select-
ive receptor agonist fluprostenol, and thrombin also stimu-
lated ERK phosphorylation in the stellate cells (Figure 4D),
while they did not induce Akt phosphorylation (data not
shown). The effect of PGE2 and fluprostenol on ERK
phosphorylation did not seem to involve cAMP, since
forskolin did not stimulate ERK phosphorylation.
In human hepatic stellate cells several growth-stimulatory
agents, including PDGF and thrombin, stimulate an acute
PGE2 production, as well as a delayed induction of COX-2,
and pretreatment with a COX inhibitor enhances their
growth stimulatory effect [31]. We examined the effect of
pretreatment with indomethacin on PDGF-stimulated
DNA synthesis in the pancreatic stellate cells. These ex-
periments showed that pretreatment with indomethacin
did not affect PDGF-stimulated DNA synthesis in the
pancreatic stellate cells (Figure 4B).
Treating the stellate cells with PGE2 did not significantly
affect the basal DNA synthesis, but attenuated PDGF-
stimulated DNA synthesis. PGE2 exerted an inhibitory
effect, which was significant at a concentration of 1 μM
(Figure 5A). This effect was mimicked by forskolin
(Figure 5B). cAMP levels were elevated above the basal
level for at least 60 minutes following stimulation with
PGE2 (Figure 5C) or forskolin (Figure 5D). Neither flu-
prostenol nor thrombin had any effect on DNA synthesis,
alone or in combination with PDGF (data not shown).
PGE2 inhibits collagen synthesis in PSC
In agreement with previous findings [6,45,46] treating
the stellate cells with TGFβ enhanced collagen synthesis,
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whereas PDGF or EGF did not significantly affect collagen
synthesis (Figure 6A). In agreement with the lack of in-
duction of COX-2 by TGFβ in the stellate cells, pretreat-
ment with indomethacin did not affect TGFβ-induced
collagen synthesis (Figure 6B). Both PGE2 and forskolin
inhibited TGFβ-stimulated collagen synthesis, suggesting
that this was a cAMP-mediated effect (Figure 7A, B, C).
While we were preparing this manuscript, Charo et al.
reported that PGE2 stimulated the mRNA expression
of collagen 1A1 in an immortalized human pancreatic
stellate cell line [40]. To examine this further, RNA
was extracted from cultured pancreatic stellate cells and
assessed for elevated gene expression of collagen 1A1 by
real time RT-qPCR. While TGFβ increased gene expres-
sion, PGE2 alone showed a slight inhibitory effect, and sig-
nificantly attenuated TGFβ-stimulated increase in gene
expression of collagen 1A1 at a concentration of 1 μM
(Figures 7D, 7E). Since PGE2 might elevate cAMP levels
through EP2 or EP4 receptors, we examined the effect of
EP2 and EP4 receptor antagonists on collagen synthesis.
We found that the EP4 receptor antagonist L161982
did not abrogate the effect of PGE2 on TGFβ-induced
collagen synthesis (Figure 7F) whereas results with the
EP2 receptor antagonist AH 6809 were not conclusive
(data not shown).
Discussion
In the present study we have demonstrated that PGE2
inhibits both collagen and DNA synthesis in human
pancreatic stellate cells from pancreatic adenocarcinoma.
These effects are mediated by increased cAMP production.
It is well known that in fibroblasts from lung and other tis-
sues, PGE2 inhibits proliferation by activating Gs-coupled
EP2 and/or EP4 receptors [23-25,41,47,48]. Since EP4 in-
hibition affected neither the cAMP response nor the effect
on collagen synthesis by PGE2 in our study, it is most likely
that EP2 receptors mediate these inhibitory effects of PGE2
on cAMP and collagen synthesis. However, due to incon-
clusive results with the EP2 receptor antagonist, these
mechanisms require further experimental confirmation.
In human hepatic stellate cells, thrombin and PDGF
stimulate the release of PGE2, which exerts an inhibitory
effect on DNA synthesis induced by PDGF and thrombin
[31]. However, PGE2 appeared to mediate the mitogenic
effect of EGF in BALB/c 3 T3 cells, and of PDGF in Swiss
3 T3 cells [49,50]. In our study, EGF, PGE2 and thrombin,
but not PDGF, consistently induced COX-2 protein expres-
sion in the stellate cells.
Pretreatment of the cells with indomethacin did not
affect PDGF-stimulated DNA synthesis, suggesting that
COX-2 induction and PGE2 production neither mediated
nor modulated PDGF-stimulated DNA synthesis. While
we did not measure production of PGE2, studies in various
cells, including pancreatic stellate cells [40], indicate that
levels are in the nanomolar range. We did not detect an
effect of PGE2 on DNA synthesis in the stellate cells when
it was added alone, however, PGE2, as well as forskolin,
inhibited PDGF-stimulated DNA synthesis, suggesting
that this effect was mediated by cAMP. This is in contrast
(See figure on previous page.)
Figure 1 COX-2 expression in formalin-fixed, paraffin-embedded tumour tissue from pancreatic cancer and isolated pancreatic stellate
cells. A. Immunohistochemistry of COX-2 expression in tumour tissue from pancreatic cancer. COX-2 positive cells - red colour, fibrotic stroma
αSMA positive - brown colour. B. Immunofluorescence of COX-2 expression in tumour tissue from pancreatic cancer. COX-2 positive cells - red
colour, stroma αSMA positive - green colour. C. Immunofluorescence staining of cultured pancreatic stellate cells, passage five; COX-2 positive
cells - red colour, αSMA positive cells - green colour, nucleus -blue colour. D. Expression of COX-2 and αSMA in different cell passage numbers.
E. Expression of EP2 receptors, TGFβ receptors and PDGF receptors in two different cell passages F. Induction of COX-2 protein by EGF (10 nM),
TGFβ (10 ng/ml), PGE2 (10 uM), and PDGF (10 ng/ml) in two different cell passages. Cells in serum-free medium were stimulated with agonists for
24 hours before cells were harvested and lysates examined by Western blots as described in Methods. Results are from one representative
experiment of four. G. Concentration dependent induction of COX-2 protein by IL-1β. Cells were stimulated in serum-free medium for 24 hours.
Results are from one typical experiment of three.
GAPDH
COX-2
Control Panc-1 HPAFII BxPc-3
GAPDH
COX-2
Control BxPc-3
BxPc-3
+Il-1Ra
A.
B.
Figure 2 Induction of COX-2 protein in pancreatic stellate cells
by indirect coculture with pancreatic adenocarcinoma cell lines.
A. Effect of coculture with Panc-1, HPAFII, and BxPC-3 cells. Cells
were cocultured in serum-free medium for 48 hours, before harvesting
and analysis by Western blots as described in Methods. Results are
from one typical of three experiments. B. Inhibition of COX-2 induction
by coculture with BxPC-3 cells when stellate cells were pretreated with
IL-1 receptor antagonist (1 μg/ml) for 1 hour before coculture for
48 hours. Results are from one typical of four experiments.
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to findings in rat pancreatic stellate cells, where treatment
of the cells with conditioned medium from the Panc-1
adenocarcinoma cell line induced COX-2 expression and
stimulated DNA synthesis [51]. Furthermore, inhibition of
COX-2 activity with the COX-2 specific inhibitor NS-398
attenuated DNA synthesis in the rat stellate cells, albeit at
high concentrations of the inhibitor, which may lead to
nonspecific effects. Thus, at high concentrations of
NS-398, inhibition of DNA synthesis has been reported
in COX-2 expressing cell lines as well as in cell lines
without COX-2 expression [52-54].
Pancreatic stellate cells are believed to be essential in
the development of fibrosis associated with chronic
pancreatitis and pancreatic cancer [4-6,10]. However,
the role of PGE2 in pancreatic fibrosis is unknown.
TGFβ has been found to induce COX-2, which attenuates
the profibrotic effect of TGFβ, in lung fibroblasts and hep-
atic stellate cells [30,48], and exogenous addition of PGE2
inhibited TGFβ-induced collagen expression in hepatic
stellate cells [30]. However, we found no induction of
COX-2 by TGFβ in the pancreatic stellate cells, and prein-
cubation of the cells with indomethacin did not affect
TGFβ-stimulated collagen synthesis. In the lung, PGE2
has been found to inhibit collagen synthesis by activating
EP2 receptors and stimulating cAMP accumulation. In pa-
tients with idiopathic pulmonary fibrosis, lung fibroblasts
display a diminished capacity to express COX-2 and to
synthesize PGE2. This results in decreased levels of PGE2
and excessive fibroblast activation with massive fibrosis
[41,47,48]. Our findings in the pancreatic stellate cells are
consistent with these studies. Treatment with PGE2, as
well as forskolin, suppressed the increase in collagen
synthesis stimulated by TGFβ, suggesting that this effect
was mediated by cAMP. Our observations are thus in
disagreement with findings in an immortalized human
pancreatic stellate cell line, where 100 nM PGE2 was
found to induce mRNA of collagen 1A1 as well as other
structural genes involved in extracellular matrix forma-
tion [40]. We therefore examined the effect of PGE2 in
our stellate cells, and found no evidence of collagen
1A1 mRNA induction. Rather, PGE2 (1 μM) attenuated
the TGFβ-induced expression of collagen 1A1, which is
in agreement with our findings of an inhibitory effect of
PGE2 on collagen synthesis. The possibility that immor-
talized pancreatic stellate cells behave differently from
primary cell lines needs consideration. Interestingly, the
effects of PGE2 on immortalized stellate cells were me-
diated by activation of EP4 receptors [40]. We have
found no evidence of EP4 receptor involvement in the
cAMP response in our primary stellate cells, however, we
can presently not exclude the possibility that EP4 recep-
tors signal via G protein-independent pathways [22].
We observed that PGE2 stimulated ERK phosphorylation
in the stellate cells. This effect was mimicked by thrombin
and the FP selective agonist fluprostenol, but not by for-
skolin, suggesting that it was a cAMP-independent effect.
Thus, the stellate cells may express other EP receptors or
FP receptors that mediate this effect. PGE2 has been
reported to stimulate fibroblast proliferation through
activation of EP1, EP3, or FP signalling in lung and cardiac
fibroblasts, as well as in NIH 3 T3 cells [26-29]. If other
prostaglandin receptors could stimulate proliferation of
pancreatic stellate cells, the inhibitory effect of cAMP in-
duced by EP2 receptors, appear to suppress these effects.
It is notable that the inhibitory effect of PGE2 on collagen
and DNA synthesis was only significant at a concentration
of 1 μM, whereas in lung fibroblasts effects have been
observed at concentrations as low as 10 nM [41]. In a
comparative study of fibroblasts from lung and gingiva,
it was observed that stimulation with PGE2 resulted in
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Figure 3 PGE2-stimulated cAMP accumulation in pancreatic stellate cells. A. Dose-dependent effect of PGE2 in the absence and presence of
0.5 mM isobutylmethylxanthine (IBMX). Cells were cultured as described in Methods, and were stimulated for 5 minutes. Results are presented as
mean + S.E.M. of three replicates from one representative of three experiment. B. Effect of EP4 receptor antagonist (L161982, 10 μM) and EP2
receptor antagonist (AH6809, 30 μM) on PGE2-stimulated cAMP accumulation (1 μM PGE2). Cells were preincubated with antagonists for 30 minutes
before stimulation with PGE2 for 15 minutes in the presence of 0.5 mM IBMX. Results are presented as mean ± S.E.M. of five experiments.
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less cAMP accumulation in gingival fibroblasts than in
lung fibroblasts [55]. Furthermore, EP3 receptor activa-
tion induced phosphorylation of c-Jun NH2-terminal
kinase (JNK), which also mediated TGFβ-stimulated fi-
brosis. Thus, simultaneous EP3 receptor activation
might reduce EP2-stimulated cAMP accumulation and
blunt the inhibitory effect on DNA and collagen synthe-
sis. Further studies, using subtype-specific agonists, or
knockdown of prostaglandin receptors, are required to
explore the role of other prostaglandin receptors on
proliferation and fibrosis in the stellate cells.
Several previous studies have demonstrated that COX-2
is overexpressed in most human pancreatic cancers
[12-16,56-60]. However, only a few publications have
addressed COX-2 expression in pancreatic stellate cells
and they reported no detectable COX-2 expression in
the stroma [16,60]. In our study, immunohistochemical
analysis carried out with a specific monoclonal antibody
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Figure 4 Effect of different agonists on DNA synthesis and phosphorylation of ERK and Akt in pancreatic stellate cells. A. Effect of PDGF
(10 ng/ml), EGF (10 nM), and TGFβ (10 ng/ml) on DNA synthesis. Cells in serum-free medium were stimulated for 24 hours, with [3H] thymidine
added at 18 hours. DNA synthesis was assessed as described in Methods. Results are presented as mean +/−SEM of six experiments. B. Effect of
pretreatment with indomethacin (10 μM) for one hour before stimulation of cells with PDGF for 24 hours. Results are presented as mean +/−SEM
of three experiments. C. Effect of PDGF (10 ng/ml), EGF (10 nM), and TGFβ (10 ng/ml) on phosphorylation of Akt and ERK. Cells in serum-free
medium were stimulated for 5 minutes before harvesting and analysis of cell lysates on Western blots. Blots are from one typical of four experiments.
Histograms represent mean +/−SEM of four experiments. D. Effect of thrombin (1 U/ml), PGE2 (10 μM), fluprostenol (10 μM), and forskolin (10 μM) on
ERK phosphorylation. Cells were stimulated for 5 minutes before harvesting. Blots from one typical of four experiments are shown. Histograms
represent mean +/−SEM of four experiments. * Sign. different from control.
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revealed no detectable COX-2 expression in the stroma –
neither in the normal pancreas nor in the pancreatic
cancer. In contrast Charo et al. [40] reported COX-2
expression in the stroma. One reason for the discrepancy
in the results could be the use of different antibodies. For
immunohistochemical staining in the study presented by
Charo [40] the polyclonal rabbit antihuman COX-2 anti-
body was used. It is known that polyclonal antibodies are
more sensitive, but do not show as high specificity, as
monoclonal antibodies [61]. To confirm the expression of
COX-2 in pancreatic stroma, Charo at al [40] performed
RT-PCR on isolated stellate cells. However, it is likely that
the isolation process itself could cause activation of the
stellate cells and increase the COX-2 expression [62].
Expression of COX-2 in cultured pancreatic stellate
cells is well documented [40,51,63] and our results sup-
port these findings. In the immunofluorescence double
staining of the cultured pancreatic stellate cells, only cells
with positive expression for αSMA were additionally posi-
tive for COX-2. The COX-2 staining was perinuclear and
Co
lla
ge
n 
sy
nt
he
si
s, 
%
 o
f c
on
tr
ol
0
50
100
200
250
150
Control
TGFβ
0
50
100
150
200
Co
lla
ge
n 
sy
nt
he
si
s, 
%
 o
f c
on
tr
ol
Control Indometacin
A. B.
*
Control TGFβ PDGF EGF
Figure 6 Effects of different agonists on collagen synthesis. A. Effect of TGFβ (10 ng/ml), PDGF (10 ng/ml) and EGF (10 nM) on collagen
synthesis. Cells were cultured and stimulated with agonists for 48 hours, as described in Methods. [3H] proline was present for the last 24 hours of
stimulation. Collagen was precipitated and radioactivity in collagen was determined as described in Methods. Results are presented as mean ± S.E.M.
of five experiments. B. Effect of pretreatment with indomethacin (10 μM) for one hour before stimulation of cells with TGFβ for 48 hours. Results are
presented as mean ± S.E.M. of three experiments. * Significantly different from control.
D
N
A
 s
yn
th
es
is
, %
 o
f c
o
n
tr
o
l
0
100
200
300
Control PGE210-8M PGE210-7M PGE210-6M
PDGF
Control
D
N
A
 s
yn
th
es
is
, %
 o
f c
on
tr
ol
0
100
200
300
400
Control
PDGF
Control Forskolin 
Control
PGE2
cA
M
P, 
pm
ol
/m
g 
pr
ot
ei
n
0
50
100
150
200
0 5 15 30 45 60
Time, min
Control
Forskolin
cA
M
P, 
pm
ol
/m
g 
pr
ot
ei
n
0
50
100
150
200
0 5 15 30 45 60
Time, min
A. B.
C. D.
*
**
*
**
10-6M
Figure 5 Effect of PGE2 and forskolin on DNA synthesis and cAMP accumulation. A. Effect of increasing concentrations of PGE2 on PDGF-stimulated
DNA synthesis. Results are presented as mean ± S.E.M. of four experiments. B. Effect of 1 μM forskolin on PDGF- stimulated DNA synthesis. Results are
presented as mean ± S.E.M. of four experiments. C. Time-dependent effect of 1 μM PGE2 on cAMP accumulation in the absence of IBMX. Results are
from one typical of four experiments and are presented as mean ± S.E.M. of triplicates. D. Time-dependent effect of 5 μM forskolin on cAMP
accumulation in the absence of IBMX. Results are from one typical of four experiments and are presented as mean ± S.E.M. of triplicates. * Sign.
different from control. ** Sign. different from PDGF alone.
Pomianowska et al. BMC Cancer 2014, 14:413 Page 10 of 13
http://www.biomedcentral.com/1471-2407/14/413
was constant in different passages (data not shown).
COX-2 expression could be further induced by stimu-
lating the stellate cells with IL-1β, EGF, thrombin, and
PGE2. Also, indirect coculture with the BxPC-3 cell
line, but not HPAFII or Panc-1 cells, induced COX-2
expression. Pretreatment of the stellate cells with IL-1
receptor antagonist blocked the induction of COX-2
induced by BxPC-3 cells, which is consistent with the fact
that the BxPC-3 cell line is known to produce IL-1α [64].
Interestingly, conditioned medium from Panc-1 cells in-
duced COX-2 in rat pancreatic stellate cells, however, how
this was mediated was not examined [51].
Conclusions
The present results show that COX-2 is mainly expressed
in carcinoma cells, and suggest that the cancer cells are
the main source of PGE2 in pancreatic tumours. In the
pancreatic stellate cells, PGE2 exerts both antiproliferative
and antifibrotic effects. These effects of PGE2 are medi-
ated by the cAMP pathway and suggests a role of EP2
receptors. Inhibition of COX-2 may inadvertently acceler-
ate fibrosis progression in pancreatic cancer.
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